SCRIPPS RESEARCH INSTITUTE
Reduce your risk when donating: see where the money actually goes.
Reduce your risk when donating: see where the money actually goes.
Cite this
Plain text SCRIPPS RESEARCH INSTITUTE. furp.org, nonprofit organization profile, tax years 2009–2024. https://furp.org/org/scripps-research-institute-330435954. Retrieved 2026-11-10.
APA furp.org. (n.d.). SCRIPPS RESEARCH INSTITUTE [Nonprofit organization profile; tax years 2009–2024]. Retrieved November 10, 2026, from https://furp.org/org/scripps-research-institute-330435954
MLA “SCRIPPS RESEARCH INSTITUTE.” furp.org, tax years 2009–2024, https://furp.org/org/scripps-research-institute-330435954. Accessed 10 Nov. 2026.
Retrieved 2026-11-10; covers tax years 2009–2024. Data: furp.org (index © the FURP Alliance; the records are public domain).
2024 · Form 990 · revenue $698.6M · expenses $537.5M · assets $1.46B
- EIN
- 33-0435954
- Address
- 10550 N TORREY PINES RD, LA JOLLA, CA 92037-1000
- Website
- WWW.SCRIPPS.EDU
- NTEE code
- H92 Biomedicine, Bioengineering Research (Medical Research) published (IRS Business Master File)
- FURP topic
- science: research education (from its 990 text; the topic index)
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (corporation)
- Ruling date
- January 1991 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Public charity supported by the public (170(b)(1)(a)(vi))
- Cross-check
- ProPublica Nonprofit Explorer
Mission
THE SCRIPPS RESEARCH INSTITUTE ("TSRI") PERFORMS HIGH IMPACT BASIC BIOMEDICAL RESEARCH, IMPROVES THE HUMAN CONDITION BY FOSTERING TRANSLATION OF ITS DISCOVERIES INTO USEFUL PRODUCTS AND ENGAGES IN THE HIGHEST QUALITY GRADUATE SCIENTIFIC EDUCATION AND POST GRADUATE SCIENTIFIC TRAINING. TSRI IS KNOWN FOR ITS ENTREPRENEURIAL ENVIRONMENT AND ITS EMPHASIS IN RESEARCH RELATING TO SYNTHETIC CHEMISTRY, THE RELATIONSHIP BETWEEN MOLECULAR STRUCTURE AND ACTIVITY AND CHEMICAL BIOLOGY.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
68 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Peter G Schultz | PRESIDENT/CEO | 2015-2024 | $1,859,240 | $10,948,835 | 3 |
| Eric Topol | PROFESSOR/EXEC VP | 2017-2024 | $1,085,635 | $8,344,879 | 2 |
| James R Williamson | FRMR VP RES&ACAD AFFS(END 1/23)/PROF | 2014-2024 | $388,715 | $4,830,477 | 1 |
| Jared M Machado | TREASURER/CHIEF ACCOUNTING OFFICER | 2015-2024 | $424,685 | $3,841,650 | 2 |
| Travis Scott Young | SR. DIRECTOR, CALIBR | 2018-2024 | $606,729 | $2,669,491 | 1 |
| Kelly San George | CFO VP ADM. CALIBR | 2020-2024 | $521,766 | $2,184,513 | 2 |
| Caroline Moon | CFO | 2021-2024 | $898,368 | $2,144,347 | 1 |
| Marshall Olin | GENERAL COUNSEL | 2022-2024 | $746,377 | $1,866,065 | 1 |
| Alanna Rutan | SECRETARY/CHIEF COMPLIANCE COUNSEL | 2020-2024 | $317,842 | $1,375,307 | 1 |
| Channing R Beals | CHIEF MEDICAL OFFICER | 2023-2024 | $685,542 | $1,299,120 | 1 |
| Scott Showalter | CHIEF ADVANCEMENT OFFICER | 2024 | $744,850 | $744,850 | 1 |
| Jing Li | SENIOR DIRECTOR | 2024 | $534,216 | $534,216 | 2 |
| Ardem Patapoutian | FACULTY DIRECTOR (END 10/24)/PROF | 2021-2024 | $142,661 | $488,336 | 1 |
| Benjamin Cravatt | FACULTY DIRECTOR (START 10/24)/PROF | 2024 | $430,385 | $430,385 | 1 |
| Richard A Lerner (former) | Professor | 2009-2017 | $6,980,292 | $14,439,526 | 2 |
| Douglas A Bingham (former) | SECRETARY/EVP SCRIPPS FL (END 4/22) | 2009-2021 | $459,402 | $7,416,010 | 3 |
| Michael A Marletta (former) | Past President | 2011-2015 | $1,349,698 | $5,435,999 | 3 |
| Matthew S Tremblay (former) | FORMER CHIEF OPERATING OFFICER | 2017-2023 | $180,564 | $4,272,440 | 2 |
| Donna J Weston (former) | Treasurer/CFO (end 12/26/15) | 2009-2016 | $834,147 | $3,899,693 | 1 |
| Cary E Thomas (former) | CIO | 2009-2018 | $326,908 | $3,840,425 | 1 |
| Kaye I Wynne (former) | VP Sponsored Programs | 2009-2018 | $813,428 | $3,671,923 | 1 |
| William R Roush (former) | Professor | 2009-2015 | $482,965 | $3,353,431 | 1 |
| Peter E Wright (former) | PROFESSOR | 2009-2021 | $452,409 | $3,186,239 | 1 |
| Peter K Vogt (former) | Professor/Former Exec VP | 2012-2019 | $385,892 | $3,049,571 | 1 |
| Karl Sharpless (former) | PROFESSOR | 2014-2020 | $436,091 | $2,582,572 | 1 |
| Vadim Klyushnichenko (former) | VP, PHARMACEUTICAL DEV & QUAL | 2019-2023 | $594,823 | $2,548,004 | 2 |
| Thomas E Northrup (former) | Secretary/General Counsel (end 12/4/15) | 2009-2016 | $306,260 | $2,497,571 | 1 |
| Jim C Paulson (former) | Professor/Former Interim President | 2015-2019 | $376,633 | $2,014,497 | 1 |
| Julius Rebek Jr (former) | SKAGGS INSTITUTE DIRECTOR | 2009-2012 | $489,247 | $1,947,809 | 1 |
| Gerald J Joyce (former) | DEAN OF FACULTY | 2009-2013 | $486,219 | $1,926,090 | 1 |
| Gerald Edleman (former) | DEPT. CHAIR/PROFESSOR | 2009-2011 | $492,699 | $1,477,201 | 1 |
| Roy G Smith (former) | Chairman Dept of Metabolism & Aging | 2013-2015 | $466,192 | $1,396,376 | 1 |
| Alice T Feng (former) | CFO & TREASURER (END 01/22) | 2019-2021 | $471,196 | $1,350,152 | 1 |
| Jeffrey Kelly (former) | DIRECTOR/PROFESSOR (END 09/21) | 2018-2020 | $450,799 | $1,333,719 | 1 |
| Demetrios I Andrikos (former) | FORMER SECRETARY | 2017-2021 | $241,657 | $1,225,611 | 1 |
| Mary Wang (former) | ASST. SEC./DIRECTOR SP (END 2/24) | 2019-2023 | $269,259 | $1,127,414 | 1 |
| Jin-Quan Yu Phd (former) | PROFESSOR | 2021-2022 | $415,720 | $908,056 | 1 |
| Harry Orf (former) | VP, SCIENTIFIC OPS | 2009-2011 | $301,522 | $904,993 | 1 |
| Jennifer Crosby (former) | VP PHILANTHROPY | 2019-2020 | $442,821 | $890,230 | 1 |
| Ronald L Davis (former) | Professor | 2016-2017 | $411,088 | $874,343 | 1 |
| Kevin Eastwood (former) | Strategic Ptnrshp, Sr.Dir. | 2018-2019 | $435,753 | $849,328 | 1 |
| Edward Roberts (former) | Professor | 2016-2017 | $406,553 | $809,510 | 1 |
| James Paulson (former) | PRESIDENT & TRUSTEE (THRU 9/20/15) | 2013-2014 | $434,623 | $784,630 | 2 |
| Isy H Goldwasser (former) | ENTREPRENEUR IN RESIDENCE | 2017-2023 | $780,655 | $780,655 | 2 |
| Steve A Kay (former) | Former President | 2014-2016 | $524,296 | $607,295 | 2 |
| Stephen Maricich (former) | CHIEF MEDICAL OFFICER | 2022 | $564,137 | $564,137 | 1 |
| Richard A King End 42017 (former) | Former COO | 2017-2018 | $325,000 | $521,561 | 1 |
| Gerald M Edelman (former) | CHAIRMAN | 2012 | $494,729 | $494,729 | 1 |
| Gerald F Joyce (former) | DEAN OF FACULTY | 2012 | $485,587 | $485,587 | 1 |
| Steven Steinhubl (former) | Associate Professor | 2018 | $471,129 | $471,129 | 1 |
| Pamela Garzone (former) | CHIEF MEDICAL OFFICER | 2020 | $468,384 | $468,384 | 1 |
| Tamara L Barnas (former) | Asst Secretary | 2014-2017 | $114,737 | $455,518 | 2 |
| Jeffery Kelly start 92818 (former) | Director/Professor | 2017 | $439,110 | $439,110 | 2 |
| Jeffery W Kelly (former) | Chairman | 2016 | $437,429 | $437,429 | 1 |
| Emily Holmes (former) | VP OPERA | 2019 | $375,507 | $375,507 | 1 |
| Patrick R Griffin PhD (former) | Trustee/Professor (Thru 7/20/16) | 2015 | $368,735 | $368,735 | 1 |
| Patrick R Griffin Ph D (former) | TRUSTEE | 2014 | $368,197 | $368,197 | 1 |
| Douglas A Binghamend 2719 (former) | Secretary/EVP of Scripps FL | 2018 | $364,485 | $364,485 | 1 |
| Kaye L Wynne (former) | VP. OSP | 2014 | $356,648 | $356,648 | 1 |
| Peter Schultz Ph D (former) | TRUSTEE (CEO AS OF 9/20/2015) | 2014 | $337,487 | $337,487 | 1 |
| Demetrios Andrikosstart 2719 (former) | Secretary/Legal & General Counsel | 2018 | $312,794 | $312,794 | 1 |
| Richard A King (former) | Chief Operating Officer | 2015-2016 | $298,667 | $298,667 | 1 |
| Linda A Sherman Ph D (former) | TRUSTEE | 2014 | $294,782 | $294,782 | 1 |
| Linda A Sherman PhD (former) | Trustee/Professor (Thru 9/19/16) | 2015 | $294,234 | $294,234 | 1 |
| Mary Wang start 2719 (former) | Assistant Secretary | 2018 | $124,659 | $124,659 | 1 |
| Tamara L Barnas end 2719 (former) | Assistant Secretary | 2018 | $123,990 | $123,990 | 1 |
| Paul R Schimmel end 92818 (former) | Director/Professor | 2017 | $65,485 | $65,485 | 2 |
| Paul Schimmel start 101816 (former) | Director/Professor | 2016 | $49,473 | $49,473 | 1 |
Officers and directors, no compensation reported
77 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| John D Diekman | DIRECTOR/BOARD CHAIR | 2017-2024 | 1 | $0 reported | 2 |
| Barbara Kosacz | DIRECTOR | 2023-2024 | 1 | $0 reported | 1 |
| Benedict Gross | DIRECTOR (END 10/24) | 2018-2024 | 1 | $0 reported | 1 |
| Claudia S Luttrell | DIRECTOR | 2009-2024 | 1 | $0 reported | 2 |
| Gene Lay | DIRECTOR | 2023-2024 | 1 | $0 reported | 1 |
| Gerald Chan | DIRECTOR | 2017-2024 | 1 | $0 reported | 1 |
| Herbert Wertheim | DIRECTOR | 2020-2024 | 1 | $0 reported | 1 |
| Lillian Lou | DIRECTOR | 2020-2024 | 1 | $0 reported | 1 |
| Mark Edwards | DIRECTOR | 2017-2024 | 1 | $0 reported | 2 |
| Mark Pearson | DIRECTOR | 2009-2024 | 1 | $0 reported | 1 |
| Ron Burkle | DIRECTOR | 2019-2024 | 1 | $0 reported | 1 |
| Sherry Lansing | DIRECTOR | 2018-2024 | 1 | $0 reported | 2 |
| Tom Daniel | DIRECTOR | 2020-2024 | 1 | $0 reported | 1 |
| Lou Lange | DIRECTOR (START 10/24) | 2024 | 1 | $0 reported | 1 |
| Peter C Farrell | DIRECTOR | 2024 | 1 | $0 reported | 2 |
| Jen Rubio (former) | DIRECTOR (END 12/23) | 2021-2023 | 1 | $0 reported | 1 |
| Peter C Farrell Phd D Sc (former) | DIRECTOR | 2018-2023 | 1 | $0 reported | 1 |
| Ge Li (former) | DIRECTOR (END 11/22) | 2017-2022 | 1 | $0 reported | 1 |
| Joanne Stubbe (former) | DIRECTOR (END 1/23) | 2020-2022 | 1 | $0 reported | 1 |
| Bernard Saint-Donat Phd (former) | DIRECTOR (END 10/21) | 2012-2021 | 1 | $0 reported | 2 |
| Christopher T Walsh (former) | DIRECTOR (END 06/22) | 2016-2021 | 1 | $0 reported | 2 |
| William R Hearst Iii (former) | DIRECTOR (END 01/22) | 2016-2021 | 1 | $0 reported | 2 |
| John Martin (former) | DIRECTOR (END 05/21) | 2018-2020 | 1 | $0 reported | 1 |
| Peter C Farell Phd D Sc (former) | DIRECTOR | 2019-2020 | 1 | $0 reported | 1 |
| Isy Goldwasser end 070520 (former) | Director | 2019 | 1 | $0 reported | 1 |
| Joel S Marcus end 051520 (former) | Director | 2019 | 1 | $0 reported | 1 |
| Mr Joel S Marcus (former) | Director | 2017-2018 | 1 | $0 reported | 2 |
| Herbert Boyer end 022819 (former) | Director | 2018 | 1 | $0 reported | 1 |
| Ronald Burkle (former) | Director | 2017-2018 | 1 | $0 reported | 2 |
| Herbert Boyer (former) | Director | 2017 | 1 | $0 reported | 2 |
| Peter C Farrell PhD DSc (former) | Director | 2012-2017 | 1 | $0 reported | 2 |
| Benedict Gross start 92818 (former) | Director | 2017 | 1 | $0 reported | 2 |
| Sherry Lansing start 50718 (former) | Director | 2017 | 1 | $0 reported | 1 |
| John Martin start 50718 (former) | Director | 2017 | 1 | $0 reported | 1 |
| Herb Boyer start 101816 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Ron Burkle start 33117 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Gerald Chan start 101816 (former) | Director | 2016 | 1 | $0 reported | 1 |
| John D Diekman start 13017 (former) | Board Chair | 2016 | 1 | $0 reported | 1 |
| Mark Edwards start 100116 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Richard A Gephardt (former) | Director (end 4/18/17) | 2009-2016 | 1 | $0 reported | 1 |
| Isy Goldwasser start 100116 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Ge Li start 13017 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Joel S Marcus start 51517 (former) | Director | 2016 | 1 | $0 reported | 1 |
| Marshall M Criser III (former) | Trustee (Thru 12/1/15) | 2012-2015 | 1 | $0 reported | 1 |
| John Davis (former) | Trustee (Thru 1/31/16) | 2012-2015 | 1 | $0 reported | 1 |
| Richard J Elkus Jr (former) | Trustee (Thru 1/31/16) | 2009-2015 | 1 | $0 reported | 1 |
| Dennis M Fenton PhD (former) | Trustee (Thru 11/12/15) | 2012-2015 | 1 | $0 reported | 1 |
| Marjorie Fink (former) | Trustee (Thru 1/31/16) | 2009-2015 | 1 | $0 reported | 1 |
| James E LaBelle MD MBA (former) | Trustee (Thru 9/19/16) | 2012-2015 | 1 | $0 reported | 1 |
| William H Molloie (former) | Trustee (Thru 9/19/16) | 2012-2015 | 1 | $0 reported | 1 |
| Edward J Sanderson Jr (former) | Trustee (Thru 12/11/15) | 2014-2015 | 1 | $0 reported | 1 |
| Lynn Schenk (former) | Trustee (Thru 9/19/16) | 2009-2015 | 1 | $0 reported | 1 |
| Mark S Skaggs (former) | Trustee (Thru 9/19/16) | 2009-2015 | 1 | $0 reported | 1 |
| A Richard Sloane (former) | Trustee (Thru 3/24/16) | 2014-2015 | 1 | $0 reported | 2 |
| Horacio Valeiras (former) | Trustee (Thru 11/16/15) | 2012-2015 | 1 | $0 reported | 1 |
| Alexander W Dreyfoos (former) | TRUSTEE (THROUGH 02/18/15) | 2009-2014 | 1 | $0 reported | 4 |
| Alan C Mendelson (former) | TRUSTEE (THROUGH 09/21/15) | 2012-2014 | 1 | $0 reported | 2 |
| Thomas E Dewey Jr (former) | TRUSTEE (THROUGH 02/18/15) | 2009-2014 | 1 | $0 reported | 1 |
| Thomas H Insley (former) | TRUSTEE (THROUGH 08/05/15) | 2009-2014 | 1 | $0 reported | 1 |
| Richard Sloane (former) | TRUSTEE | 2012-2013 | 1 | $0 reported | 3 |
| Amin Khoury (former) | TRUSTEE THROUGH 8/13/14 | 2009-2013 | 1 | $0 reported | 1 |
| Dr Paul L Herrling (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 2 |
| James R Mellor (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 2 |
| Warren Beatty (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| J Gary Burkhead (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Gary N Coburn (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| George H Conrades (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| J Michael Cook (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| A Brent Eastman Md (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Phillip Frost Md (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Louis L Gonda (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Steven Green (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Lawrence C Horowitz Md (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| John J Moores (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Ralph J Shapiro (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Andrew J Viterbi Phd (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
| Gerald Cohn (former) | TRUSTEE | 2009-2011 | 1 | $0 reported | 1 |
People by year
2024 · 29 people listed · 14 paid, $9.4M · 2,022 employees · 14 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| PETER G SCHULTZ | PRESIDENT/CEO | 40 | $1,784,580 | $0 | $74,660 | $1,859,240 | 3 |
| ERIC TOPOL | PROFESSOR/EXEC VP | 24 | $1,057,040 | $0 | $28,595 | $1,085,635 | 2 |
| CAROLINE MOON | CFO | 40 | $832,577 | $0 | $65,791 | $898,368 | 1 |
| MARSHALL OLIN | GENERAL COUNSEL | 40 | $672,211 | $0 | $74,166 | $746,377 | 1 |
| SCOTT SHOWALTER | CHIEF ADVANCEMENT OFFICER | 40 | $707,626 | $0 | $37,224 | $744,850 | 1 |
| CHANNING R BEALS | CHIEF MEDICAL OFFICER | 40 | $601,637 | $0 | $83,905 | $685,542 | 1 |
| TRAVIS SCOTT YOUNG | SR. DIRECTOR, CALIBR | 40 | $537,630 | $0 | $69,099 | $606,729 | 1 |
| JING LI | SENIOR DIRECTOR | 40 | $478,912 | $0 | $55,304 | $534,216 | 2 |
| KELLY SAN GEORGE | CFO VP ADM. CALIBR | 40 | $453,276 | $0 | $68,490 | $521,766 | 2 |
| BENJAMIN CRAVATT | FACULTY DIRECTOR (START 10/24)/PROF | 40 | $390,594 | $0 | $39,791 | $430,385 | 1 |
| JARED M MACHADO | TREASURER/CHIEF ACCOUNTING OFFICER | 40 | $371,821 | $0 | $52,864 | $424,685 | 2 |
| JAMES R WILLIAMSON | FRMR VP RES&ACAD AFFS(END 1/23)/PROF | 40 | $344,113 | $0 | $44,602 | $388,715 | 1 |
| ALANNA RUTAN | SECRETARY/CHIEF COMPLIANCE COUNSEL | 40 | $272,207 | $0 | $45,635 | $317,842 | 1 |
| ARDEM PATAPOUTIAN | FACULTY DIRECTOR (END 10/24)/PROF | 9 | $142,661 | $0 | $0 | $142,661 | 1 |
| JOHN D DIEKMAN | DIRECTOR/BOARD CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| BARBARA KOSACZ | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| BENEDICT GROSS | DIRECTOR (END 10/24) | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GENE LAY | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD CHAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| HERBERT WERTHEIM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| LILLIAN LOU | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| LOU LANGE | DIRECTOR (START 10/24) | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK EDWARDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| MARK PEARSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| RON BURKLE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHERRY LANSING | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| TOM DANIEL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
2023 · 30 people listed · 15 paid, $9.3M · 1,992 employees · 14 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| PETER G SCHULTZ | PRESIDENT/CEO | 40 | $1,719,942 | $0 | $75,701 | $1,795,643 | 3 |
| ERIC TOPOL | PROFESSOR/EXEC VP | 40 | $1,055,042 | $0 | $29,206 | $1,084,248 | 2 |
| CAROLINE MOON | COO (END 9/24)/CFO | 40 | $794,373 | $0 | $68,471 | $862,844 | 1 |
| ISY H GOLDWASSER | ENTREPRENEUR IN RESIDENCE | 40 | $739,338 | $0 | $41,317 | $780,655 | 2 |
| MARSHALL OLIN | GENERAL COUNSEL | 40 | $584,449 | $0 | $76,054 | $660,503 | 1 |
| TRAVIS SCOTT YOUNG | SR. DIRECTOR, CALIBR | 40 | $566,858 | $0 | $57,607 | $624,465 | 1 |
| CHANNING R BEALS | CHIEF MEDICAL OFFICER | 40 | $529,571 | $0 | $84,007 | $613,578 | 1 |
| VADIM KLYUSHNICHENKO | VP, PHARMACEUTICAL DEV & QUAL | 40 | $562,460 | $0 | $32,363 | $594,823 | 2 |
| KELLY SAN GEORGE | CFO VP ADM. CALIBR | 40 | $461,839 | $0 | $69,228 | $531,067 | 2 |
| JAMES R WILLIAMSON | VP, RSCH & ACAD AFFAIRS (END 1/23) | 40 | $385,731 | $0 | $46,402 | $432,133 | 1 |
| JARED M MACHADO | TREASURER/CHIEF ACCOUNTING OFFICER | 40 | $360,003 | $0 | $50,895 | $410,898 | 2 |
| ALANNA RUTAN | SECRETARY/CHIEF COMPLIANCE OFFICER | 40 | $261,520 | $0 | $41,709 | $303,229 | 1 |
| MARY WANG | ASST. SEC./DIRECTOR SP (END 2/24) | 40 | $225,864 | $0 | $43,395 | $269,259 | 1 |
| MATTHEW S TREMBLAY | FORMER CHIEF OPERATING OFFICER | 0 | $166,206 | $0 | $14,358 | $180,564 | 2 |
| ARDEM PATAPOUTIAN | FACULTY DIRECTOR/PROFESSOR | 40 | $129,755 | $0 | $1,354 | $131,109 | 1 |
| JOHN D DIEKMAN | DIRECTOR/BOARD CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| BARBARA KOSACZ | DIRECTOR (START 4/24) | 1 | $0 | $0 | $0 | $0 | 1 |
| BENEDICT GROSS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GENE LAY | DIRECTOR (START 11/23) | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD CHAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| HERBERT WERTHEIM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| JEN RUBIO | DIRECTOR (END 12/23) | 1 | $0 | $0 | $0 | $0 | 1 |
| LILLIAN LOU | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK EDWARDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| MARK PEARSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD D SC | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RON BURKLE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHERRY LANSING | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| TOM DANIEL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
2022 · 30 people listed · 15 paid, $8.6M · 2,233 employees · 13 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| PETER G SCHULTZ | PRESIDENT/CEO | 40 | $1,506,252 | $0 | $76,349 | $1,582,601 | 3 |
| ERIC TOPOL | PROFESSOR/EXECUTIVE VP | 40 | $1,063,555 | $0 | $29,380 | $1,092,935 | 2 |
| MATTHEW S TREMBLAY | CHIEF OPERATING OFFICER (END 1/23) | 40 | $919,608 | $0 | $42,104 | $961,712 | 2 |
| STEPHEN MARICICH | CHIEF MEDICAL OFFICER | 40 | $523,108 | $0 | $41,029 | $564,137 | 1 |
| TRAVIS SCOTT YOUNG | SENIOR DIRECTOR, CALIBR-SKAGGS | 40 | $485,909 | $0 | $49,173 | $535,082 | 1 |
| VADIM KLYUSHNICHENKO | VP, PHARMACEUTICAL DEV & QUAL | 40 | $491,984 | $0 | $32,525 | $524,509 | 2 |
| KELLY SAN GEORGE | CFO VP ADM. CALIBR-SKAGGS | 40 | $421,469 | $0 | $66,199 | $487,668 | 2 |
| JAMES R WILLIAMSON | VP, RSCH & ACADEMIC AFFAIRS | 40 | $441,495 | $0 | $43,794 | $485,289 | 1 |
| JARED M MACHADO | TREASURER/TREASURY & CORP. FIN. VP | 40 | $409,010 | $0 | $52,116 | $461,126 | 2 |
| MARSHALL OLIN | GENERAL COUNSEL (START 12/22) | 40 | $423,023 | $0 | $36,162 | $459,185 | 1 |
| JIN-QUAN YU PHD | PROFESSOR | 40 | $361,637 | $0 | $54,083 | $415,720 | 1 |
| CAROLINE MOON | CFO/COO (START 1/23) | 40 | $350,796 | $0 | $32,339 | $383,135 | 1 |
| ALANNA RUTAN | SECRETARY/CHIEF COMPLIANCE OFFICER | 40 | $278,751 | $0 | $29,714 | $308,465 | 1 |
| MARY WANG | ASSISTANT SECRETARY/DIRECTOR SP | 40 | $216,317 | $0 | $31,052 | $247,369 | 1 |
| ARDEM PATAPOUTIAN | DIRECTOR/PROFESSOR | 40 | $113,019 | $0 | $2,048 | $115,067 | 1 |
| JOHN D DIEKMAN | DIRECTOR/BOARD CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| BENEDICT GROSS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GE LI | DIRECTOR (END 11/22) | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD CHAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| HERBERT WERTHEIM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| JEN RUBIO | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| JOANNE STUBBE | DIRECTOR (END 1/23) | 1 | $0 | $0 | $0 | $0 | 1 |
| LILLIAN LOU | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK EDWARDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| MARK PEARSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD D SC | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RON BURKLE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHERRY LANSING | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| TOM DANIEL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
2021 · 35 people listed · 16 paid, $8.3M · 2,196 employees · 15 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| PETER G SCHULTZ | PRESIDENT/CEO | 40 | $1,239,681 | $0 | $77,183 | $1,316,864 | 3 |
| ERIC TOPOL | PROFESSOR/EXEC VP | 40 | $1,236,257 | $0 | $72,958 | $1,309,215 | 2 |
| MATTHEW S TREMBLAY | CHIEF OPERATING OFFICER | 40 | $707,113 | $0 | $80,213 | $787,326 | 2 |
| JAMES R WILLIAMSON | VP RSCH & ACADEMIC AFFAIRS | 40 | $428,506 | $0 | $74,550 | $503,056 | 1 |
| JIN-QUAN YU PHD | PROFESSOR | 40 | $416,175 | $0 | $76,161 | $492,336 | 1 |
| VADIM KLYUSHNICHENKO | VP PHARMACEUTICAL DEV & QUAL | 40 | $406,197 | $0 | $79,805 | $486,002 | 2 |
| ALICE T FENG | CFO & TREASURER (END 01/22) | 40 | $393,039 | $0 | $78,157 | $471,196 | 1 |
| TRAVIS SCOTT YOUNG | SR. DIRECTOR, CALIBR | 40 | $407,934 | $0 | $61,252 | $469,186 | 1 |
| DOUGLAS A BINGHAM | SECRETARY/EVP SCRIPPS FL (END 4/22) | 40 | $389,126 | $0 | $70,276 | $459,402 | 3 |
| PETER E WRIGHT | PROFESSOR | 40 | $378,893 | $0 | $73,516 | $452,409 | 1 |
| JARED M MACHADO | TREAS.(BEG 1/22)/VP,TREAS.&CORP.FIN. | 40 | $283,861 | $0 | $76,517 | $360,378 | 2 |
| KELLY SAN GEORGE | CFO VP ADM. CALIBR | 40 | $289,522 | $0 | $54,848 | $344,370 | 2 |
| ALANNA RUTAN | SECRETARY/CHIEF COMPLIANCE OFFICER | 40 | $234,041 | $0 | $42,444 | $276,485 | 1 |
| DEMETRIOS I ANDRIKOS | FORMER SECRETARY | 0 | $234,565 | $0 | $7,092 | $241,657 | 1 |
| MARY WANG | ASSISTANT SECRETARY/DIRECTOR SP | 40 | $206,145 | $0 | $28,667 | $234,812 | 1 |
| ARDEM PATAPOUTIAN | DIRECTOR/PROFESSOR (START 10/21) | 9 | $82,916 | $0 | $16,583 | $99,499 | 1 |
| BERNARD SAINT-DONAT PHD | DIRECTOR (END 10/21) | 1 | $0 | $0 | $0 | $0 | 2 |
| BENEDICT GROSS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| CHRISTOPHER T WALSH | DIRECTOR (END 06/22) | 1 | $0 | $0 | $0 | $0 | 2 |
| CLAUDIA S LUTTRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GE LI | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD CHAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| HERBERT WERTHEIM | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| JEN RUBIO | DIRECTOR (START 1/22) | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN D DIEKMAN | BOARD CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| JOANNE STUBBE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| LILLIAN LOU | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK EDWARDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| MARK PEARSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD D SC | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RON BURKLE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHERRY LANSING | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| TOM DANIEL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM R HEARST III | DIRECTOR (END 01/22) | 1 | $0 | $0 | $0 | $0 | 2 |
| CAROLINE MOON | CFO (START 6/22) | 40 | $0 | $0 | $0 | $0 | 1 |
2020 · 34 people listed · 16 paid, $7.9M · 2,160 employees · 17 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ERIC TOPOL | PROFESSOR/EXEC VP | 40 | $1,057,873 | $0 | $70,338 | $1,128,211 | 2 |
| PETER G SCHULTZ | PRESIDENT/CEO | 40 | $936,779 | $0 | $72,139 | $1,008,918 | 3 |
| MATTHEW S TREMBLAY | CHIEF OPERATING OFFICER | 40 | $619,874 | $0 | $74,755 | $694,629 | 2 |
| JAMES R WILLIAMSON | VP RSCH & ACADEMIC AFFAIRS | 40 | $426,678 | $0 | $71,920 | $498,598 | 1 |
| VADIM KLYUSHNICHENKO | VP PHARMACEUTICAL DEV & QUAL | 40 | $397,030 | $0 | $92,276 | $489,306 | 2 |
| PAMELA GARZONE | CHIEF MEDICAL OFFICER | 40 | $404,594 | $0 | $63,790 | $468,384 | 1 |
| JEFFREY KELLY | DIRECTOR/PROFESSOR (END 09/21) | 40 | $379,393 | $0 | $71,406 | $450,799 | 1 |
| JENNIFER CROSBY | VP PHILANTHROPY | 40 | $369,268 | $0 | $73,553 | $442,821 | 1 |
| JARED M MACHADO | TREASURER (END 10/20)/CAO | 40 | $364,993 | $0 | $76,429 | $441,422 | 2 |
| KARL SHARPLESS | PROFESSOR | 40 | $365,061 | $0 | $71,030 | $436,091 | 1 |
| ALICE T FENG | TREASURER (START 10/20)/CFO | 40 | $357,946 | $0 | $70,666 | $428,612 | 1 |
| DOUGLAS A BINGHAM | EVP SCRIPPS FL | 40 | $309,773 | $0 | $70,003 | $379,776 | 3 |
| DEMETRIOS I ANDRIKOS | SEC/VP LEGAL/GEN COUNSEL (END 01/21) | 40 | $299,186 | $0 | $73,451 | $372,637 | 1 |
| KELLY SAN GEORGE | CFO VP ADM. CALIBR | 40 | $249,114 | $0 | $50,528 | $299,642 | 2 |
| MARY WANG | ASSISTANT SECRETARY | 40 | $175,341 | $0 | $27,194 | $202,535 | 1 |
| ALANNA RUTAN | SEC./CHIEF COMP. OFF. (START 02/21) | 40 | $146,156 | $0 | $23,130 | $169,286 | 1 |
| BENEDICT GROSS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD SAINT-DONAT PHD | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| CHRISTOPHER T WALSH | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| CLAUDIA S LUTTRELL | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| GE LI | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD CHAN | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| HERBERT WERTHEIM | DIRECTOR (START 02/21) | 1 | $0 | $0 | $0 | $0 | 1 |
| JOANNE STUBBE | DIRECTOR (START 02/21) | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN D DIEKMAN | BOARD CHAIR | 1 | $0 | $0 | $0 | $0 | 2 |
| JOHN MARTIN | DIRECTOR (END 05/21) | 1 | $0 | $0 | $0 | $0 | 1 |
| LILLIAN LOU | DIRECTOR (START 06/21) | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK EDWARDS | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| MARK PEARSON | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARELL PHD D SC | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| RON BURKLE | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 1 |
| SHERRY LANSING | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
| TOM DANIEL | DIRECTOR (START 10/20) | 1 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM R HEARST III | DIRECTOR | 1 | $0 | $0 | $0 | $0 | 2 |
2019 · 32 people listed · 16 paid, $7.9M · 2,199 employees · 12 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Peter G Schultz | President/CEO | 40 | $898,378 | $0 | $71,665 | $970,043 | 3 |
| Eric Topol | Professor/Exec VP | 40 | $859,147 | $0 | $69,728 | $928,875 | 2 |
| Matthew Tremblay | Chief Operating Officer | 40 | $677,484 | $0 | $62,901 | $740,385 | 2 |
| James R Williamson | VP Rsch & Academic Affairs | 40 | $409,632 | $0 | $71,300 | $480,932 | 1 |
| Jared M Machado | Treasurer/Chief Accounting Officer | 40 | $393,518 | $0 | $75,528 | $469,046 | 2 |
| Vadim Klyushnichenko | VP Pharmaceutical Dev & Qual | 40 | $392,087 | $0 | $61,277 | $453,364 | 2 |
| Alice T Feng | CFO | 40 | $393,905 | $0 | $56,439 | $450,344 | 1 |
| Jennifer Crosby | VP Philanthropy | 40 | $372,321 | $0 | $75,088 | $447,409 | 1 |
| Jeffrey Kelly | Director/Professor | 40 | $372,601 | $0 | $70,455 | $443,056 | 1 |
| Kevin Eastwood | Strategic Ptnrshp, Sr.Dir. | 40 | $377,023 | $0 | $58,730 | $435,753 | 1 |
| Douglas A Bingham | Secretary/EVP Scripps Fl | 40 | $350,312 | $0 | $69,355 | $419,667 | 3 |
| Peter K Vogt | Professor/Former Exec VP | 40 | $315,557 | $0 | $70,335 | $385,892 | 1 |
| Jim C Paulson | Professor/Former Interim President | 40 | $304,193 | $0 | $72,440 | $376,633 | 1 |
| Emily Holmes | VP OPERA | 40 | $353,365 | $0 | $22,142 | $375,507 | 1 |
| Demetrios I Andrikos | Secretary/VP Legal & General Counsel | 40 | $299,006 | $0 | $74,736 | $373,742 | 1 |
| Mary Wang | Assistant Secretary | 40 | $148,987 | $0 | $24,452 | $173,439 | 1 |
| Benedict Gross | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Bernard Saint-Donat PhD | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Christopher T Walsh | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Claudia S Luttrell | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Ge Li | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Gerald Chan | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Isy Goldwasser end 070520 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Joel S Marcus end 051520 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| John D Diekman | Board Chair | 1 | $0 | $0 | $0 | $0 | 2 |
| John Martin | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Edwards | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Mark Pearson | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Peter C Farell PhD D Sc | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Ron Burkle | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Sherry Lansing | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| William R Hearst III | Director | 1 | $0 | $0 | $0 | $0 | 2 |
2018 · 36 people listed · 19 paid, $8.8M · 2,238 employees · 30 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Eric Topol | Professor/Exec VP | 40 | $1,046,647 | $0 | $66,612 | $1,113,259 | 2 |
| Peter G Schultz | President/CEO | 40 | $835,853 | $0 | $68,467 | $904,320 | 3 |
| Kaye I Wynne | VP Sponsored Programs | 40 | $805,233 | $0 | $8,195 | $813,428 | 1 |
| Matthew Tremblay | Chief Operating Officer | 40 | $462,068 | $0 | $56,451 | $518,519 | 2 |
| James R Williamson | VP Rsch & Academic Affairs | 40 | $406,268 | $0 | $68,088 | $474,356 | 1 |
| Steven Steinhubl | Associate Professor | 40 | $425,120 | $0 | $46,009 | $471,129 | 1 |
| Jeffrey Kelly | Director/Professor | 40 | $372,639 | $0 | $67,225 | $439,864 | 1 |
| Travis S Young | VP, Biologics | 40 | $412,774 | $0 | $21,255 | $434,029 | 1 |
| Jared M Machado | Treasurer/CFO | 40 | $355,152 | $0 | $71,981 | $427,133 | 2 |
| Karl B Sharpless | Professor | 38 | $351,983 | $0 | $67,323 | $419,306 | 1 |
| Kevin Eastwood | Strategic Ptnrshp, Sr. Dir. | 40 | $367,624 | $0 | $45,951 | $413,575 | 1 |
| Peter K Vogt | Professor/Former Exec VP | 40 | $315,548 | $0 | $67,198 | $382,746 | 1 |
| Jim C Paulson | Professor/Former Interim President | 40 | $302,070 | $0 | $69,332 | $371,402 | 1 |
| Douglas A Binghamend 2719 | Secretary/EVP of Scripps FL | 40 | $300,373 | $0 | $64,112 | $364,485 | 1 |
| Cary E Thomas | CIO | 40 | $262,912 | $0 | $63,996 | $326,908 | 1 |
| Richard A King End 42017 | Former COO | 40 | $325,000 | $0 | $0 | $325,000 | 1 |
| Demetrios Andrikosstart 2719 | Secretary/Legal & General Counsel | 40 | $254,992 | $0 | $57,802 | $312,794 | 1 |
| Mary Wang start 2719 | Assistant Secretary | 40 | $113,430 | $0 | $11,229 | $124,659 | 1 |
| Tamara L Barnas end 2719 | Assistant Secretary | 40 | $100,017 | $0 | $23,973 | $123,990 | 1 |
| Herbert Boyer end 022819 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Ronald Burkle | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Gerald Chan | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| John D Diekman | Board Chair | 1 | $0 | $0 | $0 | $0 | 2 |
| Mark Edwards | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Peter C Farrell PhD D Sc | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Isy Goldwasser | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Benedict Gross | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| William R Hearst III | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Sherry Lansing | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Ge Li | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Claudia S Luttrell | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Joel S Marcus | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| John Martin | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Pearson | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Bernard Saint-Donat PhD | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Christopher T Walsh | Director | 1 | $0 | $0 | $0 | $0 | 2 |
2017 · 36 people listed · 19 paid, $13.6M · 2,295 employees · 40 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Richard A Lerner | Professor | 29 | $6,918,267 | $0 | $62,025 | $6,980,292 | 2 |
| Peter G Schultz | President/CEO | 40 | $368,514 | $285,562 | $67,321 | $721,397 | 3 |
| Eric Topol MD | Professor/Exec VP | 40 | $562,819 | $0 | $39,682 | $602,501 | 2 |
| James R Williamson | VP Rsch & Academic Affairs | 40 | $396,719 | $0 | $67,188 | $463,907 | 1 |
| Jeffery Kelly start 92818 | Director/Professor | 40 | $372,693 | $0 | $66,417 | $439,110 | 2 |
| Karl B Sharpless | Professor | 38 | $352,726 | $0 | $66,688 | $419,414 | 1 |
| Ronald L Davis | Professor | 40 | $341,083 | $0 | $70,005 | $411,088 | 1 |
| Edward Roberts | Professor | 40 | $337,871 | $0 | $68,682 | $406,553 | 1 |
| Matthew S Tremblay | COO | 40 | $165,056 | $216,426 | $7,823 | $389,305 | 2 |
| Peter K Vogt | Professor/Former Exec VP | 40 | $315,522 | $0 | $66,558 | $382,080 | 1 |
| Kaye I Wynne | VP Sponsored Programs | 40 | $310,774 | $0 | $68,598 | $379,372 | 1 |
| Jim C Paulson | Professor/Former Interim President | 40 | $303,471 | $0 | $66,108 | $369,579 | 1 |
| Douglas A Bingham | Secretary/EVP of Scripps Florida | 40 | $301,788 | $0 | $60,656 | $362,444 | 3 |
| Jared M Machado | Treasurer/CFO | 40 | $273,430 | $0 | $65,619 | $339,049 | 2 |
| Cary E Thomas | CIO | 40 | $259,056 | $0 | $62,677 | $321,733 | 1 |
| Demetrios I Andrikos | VP Legal & General Counsel | 40 | $204,878 | $0 | $32,697 | $237,575 | 1 |
| Richard A King End 42017 | Former COO | 40 | $191,228 | $0 | $5,333 | $196,561 | 1 |
| Tamara L Barnas | Asst Secretary | 40 | $91,344 | $0 | $23,393 | $114,737 | 2 |
| Paul R Schimmel end 92818 | Director/Professor | 40 | $44,300 | $0 | $21,185 | $65,485 | 2 |
| Herbert Boyer | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Ronald Burkle | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Gerald Chan | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| John D Diekman | Board Chair | 1 | $0 | $0 | $0 | $0 | 2 |
| Mark Edwards | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Peter C Farrell PhD DSc | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Isy Goldwasser | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Benedict Gross start 92818 | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| William R Hearst III | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Sherry Lansing start 50718 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Ge Li | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Claudia S Luttrell | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Joel S Marcus | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| John Martin start 50718 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Pearson | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Bernard Saint-Donat PhD | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Christopher T Walsh | Director | 1 | $0 | $0 | $0 | $0 | 2 |
2016 · 34 people listed · 19 paid, $7.7M · 2,347 employees · 50 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Donna J Weston | Treasurer/CFO (end 12/26/15) | 0 | $834,147 | $0 | $0 | $834,147 | 1 |
| Richard A Lerner | Professor | 40 | $600,538 | $0 | $64,488 | $665,026 | 2 |
| Cary E Thomas | Chief Information Officer | 40 | $599,458 | $0 | $38,036 | $637,494 | 1 |
| Steve A Kay | Former President | 20 | $462,282 | $0 | $62,014 | $524,296 | 2 |
| Ronald L Davis | Chairman | 40 | $394,979 | $0 | $68,276 | $463,255 | 1 |
| Jeffery W Kelly | Chairman | 40 | $372,696 | $0 | $64,733 | $437,429 | 1 |
| Karl Barry Sharpless | Professor | 40 | $370,631 | $0 | $65,060 | $435,691 | 1 |
| Peter G Schultz PhD | Vice Chair/President/CEO | 24 | $362,229 | $0 | $65,605 | $427,834 | 3 |
| James R Williamson | VP Academic Affairs | 40 | $339,947 | $0 | $65,508 | $405,455 | 1 |
| Edward Roberts | Professor | 40 | $335,707 | $0 | $67,250 | $402,957 | 1 |
| Peter K Vogt | Professor/Former Exec VP | 40 | $315,508 | $0 | $64,878 | $380,386 | 1 |
| Jim C Paulson | Professor/Former Interim President | 40 | $300,912 | $0 | $66,977 | $367,889 | 1 |
| Kaye I Wynne | VP Sponsored Programs | 40 | $289,795 | $0 | $66,920 | $356,715 | 1 |
| Thomas E Northrup | Secretary/General Counsel (end 12/4/15) | 0 | $306,260 | $0 | $0 | $306,260 | 1 |
| Douglas A Bingham | Secretary/COO | 40 | $246,707 | $0 | $58,858 | $305,565 | 3 |
| Richard A King | Chief Operating Officer | 40 | $289,689 | $0 | $8,978 | $298,667 | 1 |
| Jared M Machado | Treasurer/CFO | 40 | $225,800 | $0 | $48,792 | $274,592 | 2 |
| Tamara L Barnas | Asst Secretary | 40 | $90,997 | $0 | $22,567 | $113,564 | 2 |
| Paul Schimmel start 101816 | Director/Professor | 40 | $31,129 | $0 | $18,344 | $49,473 | 1 |
| Herb Boyer start 101816 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Ron Burkle start 33117 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Gerald Chan start 101816 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| John D Diekman start 13017 | Board Chair | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Edwards start 100116 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Peter C Farrell PhD DSc | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Richard A Gephardt | Director (end 4/18/17) | 1 | $0 | $0 | $0 | $0 | 1 |
| Isy Goldwasser start 100116 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| William R Hearst III | Director (start 10/18/16) | 1 | $0 | $0 | $0 | $0 | 2 |
| Ge Li start 13017 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Claudia S Luttrell | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Joel S Marcus start 51517 | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Pearson | Director | 1 | $0 | $0 | $0 | $0 | 1 |
| Bernard Saint-Donat PhD | Director | 1 | $0 | $0 | $0 | $0 | 2 |
| Christopher T Walsh | Director (start 10/01/16) | 1 | $0 | $0 | $0 | $0 | 2 |
2015 · 38 people listed · 20 paid, $8.3M · 2,455 employees · 50 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Michael A Marletta | Past President | 40 | $1,316,151 | $0 | $33,547 | $1,349,698 | 3 |
| Richard A Lerner | Professor | 40 | $600,694 | $0 | $65,078 | $665,772 | 2 |
| Jim C Paulson | Past President | 40 | $461,195 | $0 | $67,799 | $528,994 | 1 |
| Donna J Weston | Treasurer/CFO (Thru 12/26/15) | 40 | $425,094 | $0 | $65,086 | $490,180 | 1 |
| William R Roush | Professor | 40 | $417,081 | $0 | $65,884 | $482,965 | 1 |
| Roy G Smith | Chairman Dept of Metabolism & Aging | 40 | $393,820 | $0 | $72,372 | $466,192 | 1 |
| Cary Eaton Thomas | Senior Vice President | 40 | $380,649 | $0 | $68,819 | $449,468 | 1 |
| Peter E Wright | Professor | 40 | $371,906 | $0 | $68,355 | $440,261 | 1 |
| Karl Barry Sharpless | Professor | 40 | $370,787 | $0 | $65,650 | $436,437 | 1 |
| Peter K Vogt | Professor | 40 | $315,664 | $0 | $65,468 | $381,132 | 1 |
| Patrick R Griffin PhD | Trustee/Professor (Thru 7/20/16) | 40 | $299,470 | $0 | $69,265 | $368,735 | 1 |
| Peter G Schultz PhD | President/CEO | 24 | $295,219 | $0 | $66,756 | $361,975 | 3 |
| James R Williamson | VP Academic Affairs | 40 | $294,640 | $0 | $65,839 | $360,479 | 1 |
| Kaye I Wynne | VP Office of Sponsored Programs | 40 | $289,951 | $0 | $67,510 | $357,461 | 1 |
| Thomas E Northrup | Secretary/Gen Bus Cnsl (Thru 12/4/15) | 40 | $280,843 | $0 | $62,677 | $343,520 | 1 |
| Linda A Sherman PhD | Trustee/Professor (Thru 9/19/16) | 40 | $231,320 | $0 | $62,914 | $294,234 | 1 |
| Jared M Machado | Treasurer/CFO (Start 6/4/16) | 40 | $189,436 | $0 | $43,885 | $233,321 | 2 |
| Tamara L Barnas | Executive Admin & Asst Secretary | 40 | $87,797 | $0 | $24,407 | $112,204 | 2 |
| Steve A Kay | President | 40 | $74,638 | $0 | $8,361 | $82,999 | 2 |
| Douglas A Bingham | Secretary/Exec VP | 40 | $62,083 | $0 | $14,805 | $76,888 | 3 |
| Marshall M Criser III | Trustee (Thru 12/1/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| John Davis | Trustee (Thru 1/31/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Richard J Elkus Jr | Trustee (Thru 1/31/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Peter C Farrell PhD DSc | Trustee | 1 | $0 | $0 | $0 | $0 | 2 |
| Dennis M Fenton PhD | Trustee (Thru 11/12/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| Marjorie Fink | Trustee (Thru 1/31/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Richard A Gephardt | Trustee | 1 | $0 | $0 | $0 | $0 | 1 |
| James E LaBelle MD MBA | Trustee (Thru 9/19/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Claudia S Luttrell | Trustee | 1 | $0 | $0 | $0 | $0 | 2 |
| William H Molloie | Trustee (Thru 9/19/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Pearson | Trustee | 1 | $0 | $0 | $0 | $0 | 1 |
| Bernard Saint-Donat | Trustee | 1 | $0 | $0 | $0 | $0 | 2 |
| Edward J Sanderson Jr | Trustee (Thru 12/11/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| Lynn Schenk | Trustee (Thru 9/19/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark S Skaggs | Trustee (Thru 9/19/16) | 1 | $0 | $0 | $0 | $0 | 1 |
| A Richard Sloane | Trustee (Thru 3/24/16) | 1 | $0 | $0 | $0 | $0 | 2 |
| Horacio Valeiras | Trustee (Thru 11/16/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| Richard A King | COO (Start 5/16/16) | 40 | $0 | $0 | $0 | $0 | 1 |
2014 · 40 people listed · 17 paid, $8.2M · 2,634 employees · 30 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MICHAEL A MARLETTA | PAST PRESIDENT | 0 | $1,819,610 | $0 | $67,357 | $1,886,967 | 3 |
| RICHARD A LERNER | INSTITUTE PROFESSOR | 40 | $605,279 | $0 | $64,513 | $669,792 | 2 |
| WILLIAM R ROUSH | PROFESSOR | 40 | $417,065 | $0 | $65,345 | $482,410 | 1 |
| ROY G SMITH | CHAIRMAN, METABOLISM | 40 | $394,829 | $0 | $70,824 | $465,653 | 1 |
| PETER E WRIGHT | PROFESSOR | 40 | $371,885 | $0 | $67,574 | $439,459 | 1 |
| KARL BARRY SHARPLESS | PROFESSOR | 40 | $370,763 | $0 | $64,870 | $435,633 | 1 |
| JAMES C PAULSON PHD | PRESIDENT & TRUSTEE (THRU 9/20/15) | 40 | $367,915 | $0 | $66,708 | $434,623 | 2 |
| DONNA J WESTON | SR. VP, CFO, TREASURER | 40 | $368,938 | $0 | $63,409 | $432,347 | 1 |
| CARY E THOMAS | SR. VP. | 40 | $359,710 | $0 | $68,887 | $428,597 | 1 |
| PETER K VOGT | EXEC VP & CHIEF SCI OFF | 40 | $315,639 | $0 | $64,097 | $379,736 | 1 |
| PATRICK R GRIFFIN PH D | TRUSTEE | 1 | $299,474 | $0 | $68,723 | $368,197 | 1 |
| KAYE L WYNNE | VP. OSP | 40 | $290,420 | $0 | $66,228 | $356,648 | 1 |
| JAMES R WILLIAMSON | VP OF ACAD. AFFAIRS (AS OF 9/21/15) | 40 | $272,520 | $0 | $65,037 | $337,557 | 1 |
| PETER SCHULTZ PH D | TRUSTEE (CEO AS OF 9/20/2015) | 24 | $270,890 | $0 | $66,597 | $337,487 | 1 |
| THOMAS E NORTHRUP | CHF BUS. CNSL, SECRETARY | 40 | $255,824 | $0 | $53,091 | $308,915 | 1 |
| LINDA A SHERMAN PH D | TRUSTEE | 1 | $230,574 | $0 | $64,208 | $294,782 | 1 |
| TAMARA L BARNAS | EXEC ADMIN & ASTNT SECRETARY | 40 | $86,458 | $0 | $28,555 | $115,013 | 2 |
| MARSHALL M CRISER III | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN DAVIS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD J ELKUS JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD DSC | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| DENNIS M FENTON PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARJORIE FINK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD A GEPHARDT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES E LABELLE MD MBA | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| WILLIAM H MOLLOIE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK PEARSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD SAINT-DONAT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| LYNN SCHENK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK S SKAGGS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| A RICHARD SLOANE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| HORACIO VALEIRAS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| EDWARD J SANDERSON JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS E DEWEY JR | TRUSTEE (THROUGH 02/18/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| ALEXANDER W DREYFOOS | TRUSTEE (THROUGH 02/18/15) | 1 | $0 | $0 | $0 | $0 | 4 |
| THOMAS H INSLEY | TRUSTEE (THROUGH 08/05/15) | 1 | $0 | $0 | $0 | $0 | 1 |
| ALAN C MENDELSON ESQ | TRUSTEE (THROUGH 09/21/15) | 1 | $0 | $0 | $0 | $0 | 2 |
| DOUGLAS A BINGHAM | EXEC VP, COO, SECRETARY | 40 | $0 | $0 | $0 | $0 | 3 |
| STEVE KAY | PRESIDENT (AS OF 09/20/15) | 0 | $0 | $0 | $0 | $0 | 2 |
2013 · 34 people listed · 13 paid, $8.5M · 2,775 employees · 27 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DOUGLAS A BINGHAM | FORMER EXEC VP, COO, SEC. | 40 | $2,832,526 | $0 | $18,106 | $2,850,632 | 3 |
| MICHAEL A MARLETTA | PAST PRESIDENT | 40 | $810,702 | $0 | $66,257 | $876,959 | 3 |
| RICHARD A LERNER | INSTITUTE PROFESSOR | 40 | $606,435 | $0 | $63,473 | $669,908 | 2 |
| GERALD J JOYCE | DEAN OF FACULTY | 40 | $418,308 | $0 | $67,911 | $486,219 | 1 |
| WILLIAM R ROUSH | PROFESSOR | 40 | $415,955 | $0 | $65,317 | $481,272 | 1 |
| ROY G SMITH | CHAIRMAN, METABOLISM | 40 | $394,997 | $0 | $69,534 | $464,531 | 1 |
| PETER E WRIGHT | PROFESSOR | 40 | $375,230 | $0 | $64,578 | $439,808 | 1 |
| DONNA WESTON | SR. VP, CFO, TREASURER | 40 | $368,958 | $0 | $62,486 | $431,444 | 1 |
| CARY THOMAS | SR. VP. | 40 | $359,906 | $0 | $67,785 | $427,691 | 1 |
| PETER K VOGT | EXEC VP & CHIEF SCI OFF | 40 | $315,770 | $0 | $63,648 | $379,418 | 1 |
| KAYE I WYNNE | VP. OSP | 40 | $291,156 | $0 | $64,587 | $355,743 | 1 |
| JAMES PAULSON PHD | ACTING PRES, TRUSTEE | 40 | $284,283 | $0 | $65,724 | $350,007 | 2 |
| THOMAS NORTHRUP | CHF BUS. CNSL, ASST. SEC | 40 | $255,980 | $0 | $53,051 | $309,031 | 1 |
| MARSHALL M CRISER III | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN DAVIS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS E DEWEY JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALEXANDER W DREYFOOS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| RICHARD J ELKUS JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD DSC | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| DENNIS M FENTON PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARJORIE FINK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD A GEPHARDT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS H INSLEY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| AMIN KHOURY | TRUSTEE THROUGH 8/13/14 | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES E LABELLE MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| ALAN C MENDELSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| WILLIAM H MOLLOIE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK PEARSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD SAINT-DONAT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| LYNN SCHENK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK S SKAGGS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD SLOANE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 3 |
| HORACIO VALEIRAS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2012 · 33 people listed · 12 paid, $6.0M · 2,846 employees · 45 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MICHAEL A MARLETTA | PRESIDENT | 40 | $813,347 | $0 | $62,994 | $876,341 | 3 |
| RICHARD A LERNER | INSTITUTE PROFESSOR | 40 | $614,702 | $0 | $62,652 | $677,354 | 2 |
| DOUGLAS BINGHAM | EXEC. VP, COO, SECRETARY | 40 | $576,008 | $0 | $67,448 | $643,456 | 3 |
| GERALD M EDELMAN | CHAIRMAN | 40 | $426,550 | $0 | $68,179 | $494,729 | 1 |
| JULIUS REBEK JR | SKAGGS INSTITUTE DIRECTOR | 40 | $416,293 | $0 | $72,954 | $489,247 | 1 |
| GERALD F JOYCE | DEAN OF FACULTY | 40 | $418,462 | $0 | $67,125 | $485,587 | 1 |
| WILLIAM R ROUSH | PROFESSOR | 40 | $415,953 | $0 | $64,673 | $480,626 | 1 |
| DONNA WESTON | SR. VP, CFO, TREASURER | 40 | $368,990 | $0 | $61,816 | $430,806 | 1 |
| CARY THOMAS | SR. VP. | 40 | $361,450 | $0 | $65,910 | $427,360 | 1 |
| PETER VOGT | EXEC VP & CHIEF SCIENCE OFF | 40 | $315,926 | $0 | $62,255 | $378,181 | 1 |
| KAYE WYNNE | VP. OSP | 40 | $291,316 | $0 | $63,872 | $355,188 | 1 |
| THOMAS NORTHRUP | CHF BUS. CNSL, ASST. SEC | 40 | $256,160 | $0 | $53,252 | $309,412 | 1 |
| MARSHALL M CRISER III | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN DAVIS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS E DEWEY JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALEXANDER W DREYFOOS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| RICHARD J ELKUS JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PETER C FARRELL PHD DSC | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| DENNIS M FENTON PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARJORIE FINK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD A GEPHARDT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS H INSLEY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| AMIN KHOURY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JAMES E LABELLE MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| ALAN C MENDELSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| WILLIAM H MOLLOIE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK PEARSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| BERNARD SAINT-DONAT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| LYNN SCHENK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK S SKAGGS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD SLOANE | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 3 |
| HORACIO VALEIRAS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2011 · 39 people listed · 12 paid, $6.2M · 2,937 employees · 44 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| RICHARD LERNER | OUTGOING PRESIDENT | 40 | $1,310,860 | $0 | $59,700 | $1,370,560 | 2 |
| DOUGLAS BINGHAM | EXEC. VP, COO, SECRETARY | 40 | $575,372 | $0 | $61,727 | $637,099 | 3 |
| GERALD EDLEMAN | DEPT. CHAIR/PROFESSOR | 40 | $428,756 | $0 | $63,943 | $492,699 | 1 |
| JULIUS REBEK JR | SKAGGS INSTITUTE DIRECTOR | 40 | $416,470 | $0 | $69,806 | $486,276 | 1 |
| GERALD JOYCE | DEAN OF FACULTY | 40 | $418,490 | $0 | $63,915 | $482,405 | 1 |
| WILLIAM ROUSH | PROFESSOR | 40 | $413,648 | $0 | $61,560 | $475,208 | 1 |
| PETER WRIGHT | DEPT. CHAIR/PROFESSOR | 40 | $411,096 | $0 | $59,044 | $470,140 | 1 |
| MICHAEL MARLETTA | INCOMING PRESIDENT | 40 | $438,226 | $0 | $7,808 | $446,034 | 3 |
| DONNA WESTON | SR. VP, CFO, TREASURER | 40 | $368,916 | $0 | $58,802 | $427,718 | 1 |
| KAYE WYNNE | VP. OSP | 40 | $290,426 | $0 | $61,014 | $351,440 | 1 |
| THOMAS NORTHRUP | CHF BUS. CNSL, ASST. SEC | 40 | $256,252 | $0 | $51,118 | $307,370 | 1 |
| HARRY ORF | VP, SCIENTIFIC OPS | 40 | $242,837 | $0 | $58,685 | $301,522 | 1 |
| WARREN BEATTY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J GARY BURKHEAD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GARY N COBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GEORGE H CONRADES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J MICHAEL COOK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS E DEWEY JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALEXANDER W DREYFOOS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| A BRENT EASTMAN MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD J ELKUS JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARJORIE FINK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PHILLIP FROST MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD GEPHARDT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LOUIS L GONDA | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STEVEN GREEN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PAUL L HERRLING PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| LAWRENCE C HOROWITZ MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS H INSLEY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| AMIN KHOURY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES R MELLOR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JOHN J MOORES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK PEARSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LYNN SCHENK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RALPH J SHAPIRO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK S SKAGGS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANDREW J VITERBI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD COHN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2010 · 39 people listed · 12 paid, $6.2M · 2,904 employees · 44 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| RICHARD LERNER | PRESIDENT | 40 | $1,310,860 | $0 | $59,634 | $1,370,494 | 2 |
| DOUGLAS BINGHAM | EXEC. VP, COO, SECRETARY | 40 | $575,372 | $0 | $67,750 | $643,122 | 3 |
| GERALD EDLEMAN | PROFESSOR | 40 | $427,756 | $0 | $64,877 | $492,633 | 1 |
| JULIUS REBEK JR | PROFESSOR | 40 | $416,470 | $0 | $69,740 | $486,210 | 1 |
| GERALD JOYCE | DEAN OF FACULTY | 40 | $416,040 | $0 | $64,249 | $480,289 | 1 |
| WILLIAM ROUSH | PROFESSOR | 40 | $413,648 | $0 | $61,494 | $475,142 | 1 |
| PETER WRIGHT | PROFESSOR | 40 | $411,091 | $0 | $60,950 | $472,041 | 1 |
| DONNA WESTON | SR. VP, CFO, TREASURER | 40 | $367,916 | $0 | $59,736 | $427,652 | 1 |
| CARY THOMAS | SR. VP. | 40 | $361,292 | $0 | $61,797 | $423,089 | 1 |
| KAYE WYNNE | VP. OSP | 40 | $290,426 | $0 | $60,948 | $351,374 | 1 |
| THOMAS NORTHRUP | CHF BUS. CNSL, ASST. SEC | 40 | $256,389 | $0 | $50,915 | $307,304 | 1 |
| HARRY ORF | VP, SCIENTIFIC OPS | 40 | $242,837 | $0 | $58,619 | $301,456 | 1 |
| WARREN BEATTY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J GARY BURKHEAD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GARY N COBURN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GEORGE H CONRADES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J MICHAEL COOK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS E DEWEY JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ALEXANDER W DREYFOOS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| A BRENT EASTMAN MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD J ELKUS JR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARJORIE FINK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PHILLIP FROST MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RICHARD GEPHARDT | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LOUIS L GONDA | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| STEVEN GREEN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| PAUL L HERRLING PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| LAWRENCE C HOROWITZ MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| THOMAS H INSLEY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| AMIN KHOURY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| CLAUDIA S LUTTRELL | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JAMES R MELLOR | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| JOHN J MOORES | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK PEARSON | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| LYNN SCHENK | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| RALPH J SHAPIRO | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| MARK S SKAGGS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| ANDREW J VITERBI PHD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| GERALD COHN | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2009 · 39 people listed · 12 paid, $6.2M · 2,861 employees · 47 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Richard A Lerner MD | President, CEO | 40 | $1,310,980 | $0 | $59,348 | $1,370,328 | 2 |
| Douglas Bingham | Exec. VP, COO, Secretary | 40 | $574,292 | $0 | $63,667 | $637,959 | 3 |
| Gerald Edleman | Professor | 40 | $428,999 | $0 | $62,870 | $491,869 | 1 |
| Julius Rebek Jr | Professor | 40 | $416,657 | $0 | $69,419 | $486,076 | 1 |
| Gerald Joyce | Professor | 40 | $413,994 | $0 | $63,183 | $477,177 | 1 |
| William Roush | Professor | 40 | $413,834 | $0 | $61,974 | $475,808 | 1 |
| Peter Wright | Professor | 40 | $411,309 | $0 | $60,812 | $472,121 | 1 |
| Donna Weston | Sr. VP, CFO, Treasurer | 40 | $367,947 | $0 | $57,452 | $425,399 | 1 |
| Cary Thomas | Sr. VP. | 40 | $336,813 | $0 | $61,272 | $398,085 | 1 |
| Kaye Wynne | VP. OSP | 40 | $290,646 | $0 | $60,556 | $351,202 | 1 |
| Thomas Northrup | Chf Bus. Cnsl, Asst. Sec | 40 | $255,237 | $0 | $50,522 | $305,759 | 1 |
| Harry Orf | VP, Scientific Ops | 40 | $242,957 | $0 | $59,058 | $302,015 | 1 |
| Warren Beatty | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J Gary Burkhead | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Gary N Coburn | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| George H Conrades | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| J Michael Cook | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Thomas E Dewey Jr | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Alexander W Dreyfoos | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 4 |
| A Brent Eastman MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Richard J Elkus Jr | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Marjorie Fink | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Phillip Frost MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Richard Gephardt | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Louis L Gonda | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Steven Green | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Paul L Herrling PhD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| Lawrence C Horowitz MD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Thomas H Insley | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Amin Khoury | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Claudia S Luttrell | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| James R Mellor | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 2 |
| John J Moores | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark Pearson | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Lynn Schenk | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Ralph J Shapiro | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Mark S Skaggs | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Andrew J Viterbi PhD | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| Gerald Cohn | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
Highest-paid independent contractors
2024 · 5 contractors · $7.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| KEKER VAN NEST & PETERS LLP | SAN FRANCISCO, CA | LEGAL SERVICES | $4,408,569 |
| UNIVERSAL PROTECTION SERVICES LP | PASADENA, CA | SECURITY SERVICES | $1,249,160 |
| STRATEGIC INVESTMENT GROUP | ARLINGTON, VA | INVESTMENT MANAGEMENT SERVICES | $947,691 |
| DELOITTE & TOUCHE LLP | DALLAS, TX | AUDIT SERVIES | $670,058 |
| COOLEY LLP | SAN FRANCISCO, CA | LEGAL SERVIES | $614,889 |
2023 · 5 contractors · $2.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| COOLEY LLP | SAN FRANCISCO, CA | LEGAL SERVICES | $984,266 |
| DELOITTE & TOUCHE LLP | DALLAS, TX | AUDIT SERVICES | $403,128 |
| CHARLES RIVER SEARCH LLC | NEEDHAM, MA | RECRUITING SERVICES | $325,375 |
| SCHWEGMAN LUNDBERG & WOESSNER PA | MINNEAPOLIS, MN | LEGAL SERVICES | $309,342 |
| OLSON & CEPURITIS LTD | CHICAGO, IL | LEGAL SERVICES | $281,853 |
2022 · 5 contractors · $4.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| WILSON SONSINI GOODRICH & ROSATI | LOS ANGELES, CA | LEGAL SERVICES | $1,670,277 |
| GUNSTER YOAKLEY AND STEWART PA | TAMPA, FL | LEGAL SERVICES | $870,000 |
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LEGAL SERVICES | $622,131 |
| OLSON & CEPURITIS LTD | CHICAGO, IL | LEGAL SERVICES | $541,591 |
| DELOITTE & TOUCHE LLP | DALLAS, TX | AUDIT & TAX SERVICES | $473,873 |
2021 · 5 contractors · $4.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| BEHMER & BLACKFORD LLP | SAN DIEGO, CA | LEGAL SERVICES | $1,318,311 |
| WILSON SONSINI GOODRICH & ROSATI | LOS ANGELES, CA | LEGAL SERVICES | $1,198,824 |
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LEGAL SERVICES | $857,356 |
| HOLLAND & KNIGHT LLP | ORLANDO, FL | LEGAL SERVICES | $477,698 |
| DELOITTE & TOUCHE LLP | DALLAS, TX | AUDIT & TAX SERVICES | $469,852 |
2020 · 5 contractors · $2.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LEGAL SERVICES | $540,597 |
| BEHMER & BLACKFORD LLP | SAN DIEGO, CA | LEGAL SERVICES | $513,719 |
| DELOITTE & TOUCHE LLP | DALLAS, TX | AUDIT & TAX SERVICES | $432,477 |
| COOLEY LLP | SAN FRANCISCO, CA | LEGAL SERVICES | $361,152 |
| WILSON SONSINI GOODRICH & ROSATI | LOS ANGELES, CA | LEGAL SERVICES | $256,929 |
2019 · 5 contractors · $3.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| Cooley LLP | San Francisco, CA | Legal Services | $1,036,314 |
| Wilson Sonsini Goodrich & Rosati | Los Angeles, CA | Legal Services | $688,967 |
| Deloitte & Touche LLP | Dallas, TX | Audit & Tax Services | $603,964 |
| Hogan Lovells US LLP | Miami, FL | Legal Services | $363,855 |
| Schwegman Lundberg Woessner PA | Minneapolis, MN | Legal Services | $298,699 |
2018 · 5 contractors · $4.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| Wilson Sonsini Goodrich & Rosati | Los Angeles, CA | Legal Services | $1,850,910 |
| Hogan Lovells US LLP | Miami, FL | Legal Services | $1,433,235 |
| Dorsey & Whitney LLP | Minneapolis, MN | Legal Services | $447,603 |
| Deloitte & Touche LLP | Dallas, TX | Audit & Tax Services | $378,549 |
| Cooley LLP | San Francisco, CA | Legal Services | $372,043 |
2017 · 5 contractors · $2.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| Montage Marketing Group L Mercedita Roxa | Bethesda, MD | PMI-CP - Grassroots Engagement Support | $525,883 |
| Hogan Lovells US LLP | Miami, FL | Legal Services | $468,138 |
| Deloitte & Touche LLP | Dallas, TX | Audit & Tax Services | $457,569 |
| Kilpatrick Townsend & Stockton LLP | Atlanta, GA | Legal Services | $393,556 |
| Husch Blackwell LLP | St Louis, MO | Legal Services | $335,413 |
2016 · 5 contractors · $1.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| Hogan Lovells US LLP | Miami, FL | Legal Services | $479,522 |
| Deloitte & Touche LLP | San Diego, CA | Audit & Tax Services | $468,957 |
| Schwegman Lundberg Woessner | Minneapolis, MN | Legal Services | $369,766 |
| Olson & Cepuritis Ltd | Chicago, IL | Legal Services | $269,123 |
| Kilpatrick Townsend & Stockton | San Francisco, CA | Legal Services | $265,795 |
2015 · 5 contractors · $2.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| Schwegman Lundberg Woessner PA | Minneapolis, MN | Legal Services | $598,207 |
| Olson & Cepuritis LTD | Chicago, IL | Legal Services | $444,771 |
| Deloitte & Touche LLP | San Diego, CA | Audit & Tax Services | $416,980 |
| Kilpatrick Townsend & Stockton | San Francisco, CA | Legal Services | $291,885 |
| Wilson Sonsini Goodrich | Los Angeles, CA | Legal Services | $214,904 |
2014 · 5 contractors · $2.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LAWYER | $598,207 |
| OLSON & CEPURITIS LTD | CHICAGO, IL | LAWYER | $444,771 |
| DELOITTE & TOUCHE LLP | SAN DIEGO, CA | AUDIT & TAX | $416,980 |
| KILPATRICK TOWNSEND & STO | SAN FRANCISCO, CA | LAWYER | $291,885 |
| WILSON SONSINI GOODRICH | LOS ANGELAS, CA | LAWYER | $214,904 |
2013 · 5 contractors · $2.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| OLSON & CEPURITIS LTD | LAWYER | $697,538 | |
| SCHWEGMAN LUNDBERG WOESSNER PA | LAWYER | $681,574 | |
| QUINE INTELLECTUAL | LAWYER | $495,990 | |
| DELOITTE & TOUCHE LLP | AUDIT & TAX | $271,360 | |
| KILPATRICK TOWNSEND & STO | LAWYER | $210,560 |
2012 · 5 contractors · $3.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| OLSON & CEPURITIS LTD | CHICAGO, IL | LAWYER | $1,041,829 |
| QUINE INTELLECTUAL | ALEMEDA, CA | LAWYER | $740,131 |
| KOA HILLS CONSULTING | KAMUELA, HI | CONSULTANTS | $537,735 |
| DELOITTE & TOUCHE LLP | SAN DIEGO, CA | AUDIT & TAX | $423,891 |
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LAWYER | $379,163 |
2011 · 5 contractors · $3.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| OLSON & CEPURITIS LTD | CHICAGO, IL | LAWYER | $950,720 |
| FITCH CONTRACTING | LAKESIDE, CA | ROOFING CONTRACTORS | $926,388 |
| QUINE INTELLECTUAL | ALEMEDA, CA | LAWYER | $563,362 |
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LAWYER | $470,956 |
| DELOITTE & TOUCHE LLP | SAN DIEGO, CA | AUDIT & TAX | $448,331 |
2010 · 5 contractors · $2.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| OLSON & CEPURITIS LTD | CHICAGO, IL | LEGAL | $982,421 |
| QUINE INTELLECTUAL | ALEMEDA, CA | PATENT ATTORNEY | $667,193 |
| DELOITTE & TOUCHE LLP | SAN DIEGO, CA | AUDIT & TAX | $524,063 |
| SCHWEGMAN LUNDBERG WOESSNER PA | MINNEAPOLIS, MN | LEGAL | $499,199 |
| DLA PIPER US LLP | BALTIMORE, MD | LEGAL | $226,135 |
2009 · 5 contractors · $2.7M
| Name | Location | Service | Paid |
|---|---|---|---|
| Deloitte & Touche LLP | San Diego, CA | Audit & Tax | $684,869 |
| Olson & Cepuritis LTD | Chicago, IL | Legal | $661,901 |
| Quine Intellectual | Alemeda, CA | Patent Attorney | $580,555 |
| Schwegman Lundberg Woessner PA | Minneapolis, MN | Legal | $455,759 |
| Xnth | Maitland, FL | Architectural Design | $354,745 |
Paid as a vendor by
Other organizations that listed this one among their highest-paid independent contractors. Contractor lists give no EIN, so these are matched on name and address; check the filing.
Who the money went to
Grants this organization reported paying: Schedule I Part II of the Form 990, or the grants-paid list on the 990-PF. Open a year for every recipient. Recipients link to their own page when the grant names an EIN we have (990-PF grants list no EIN, so those link only on an exact, unique name and state). Grants to individuals are counted; their names are not shown.
2024 · 141 grants to organizations · $78.6M
Listed grants add up to $78,615,159; the return's “grants paid” expense line says $117,089,363. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2023 · 141 grants to organizations · $93.9M
Listed grants add up to $93,947,562; the return's “grants paid” expense line says $127,840,846. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2022 · 99 grants to organizations · $69.5M
Listed grants add up to $69,477,912; the return's “grants paid” expense line says $84,931,251. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2021 · 94 grants to organizations · $451.9M
Listed grants add up to $451,901,542; the return's “grants paid” expense line says $467,412,781. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2020 · 91 grants to organizations · $67.3M
Listed grants add up to $67,280,843; the return's “grants paid” expense line says $82,523,976. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2014 · 1 grant to organizations · $750K
Listed grants add up to $750,000; the return's “grants paid” expense line says $13,848,564. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2010 · 1 grant to organizations · $1.4M
Listed grants add up to $1,400,000; the return's “grants paid” expense line says $9,252,225. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
Negative amounts are returned or refunded grants; they are listed last and left out of the totals of grants paid.
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $698,624,318 | $537,453,981 | $1,460,616,898 | $1,153,851,554 | $317,961,835 | $1,811,390 | $4,814,094 | 2,022 | 14 |
| 2023 · Form 990 | ||||||||
| $641,106,163 | $528,437,793 | $1,299,917,796 | $931,789,215 | $370,268,955 | $2,212,057 | $4,444,304 | 1,992 | 14 |
| 2022 · Form 990 | ||||||||
| $815,837,195 | $532,639,503 | $1,088,712,998 | $758,238,281 | $395,238,681 | $6,286,258 | $5,207,183 | 2,233 | 13 |
| 2021 · Form 990 | ||||||||
| $634,980,417 | $884,961,642 | $828,320,768 | $448,836,848 | $385,396,446 | $1,280,071 | $4,466,925 | 2,196 | 15 |
| 2020 · Form 990 | ||||||||
| $537,087,759 | $473,843,953 | $1,160,188,604 | $722,008,424 | $418,691,076 | $2,261,518 | $4,764,214 | 2,160 | 17 |
| 2019 · Form 990 | ||||||||
| $414,846,612 | $444,003,884 | $973,580,297 | $651,628,455 | $361,859,000 | $2,222,378 | $4,294,526 | 2,199 | 12 |
| 2018 · Form 990 | ||||||||
| $412,183,981 | $432,597,967 | $962,297,107 | $680,840,800 | $366,278,398 | $2,851,883 | $4,032,011 | 2,238 | 30 |
| 2017 · Form 990 | ||||||||
| $380,130,505 | $373,107,791 | $791,941,824 | $642,933,844 | $347,588,971 | $2,371,336 | $4,642,511 | 2,295 | 40 |
| 2016 · Form 990 | ||||||||
| $340,849,538 | $366,352,436 | $787,833,020 | $632,124,163 | $315,969,113 | $2,686,122 | $2,861,354 | 2,347 | 50 |
| 2015 · Form 990 | ||||||||
| $348,588,706 | $364,687,971 | $795,642,918 | $637,000,978 | $323,083,434 | $2,855,648 | $5,401,827 | 2,455 | 50 |
| 2014 · Form 990 | ||||||||
| $362,462,868 | $382,942,496 | $803,333,192 | $647,190,157 | $315,512,724 | $3,853,580 | $4,227,833 | 2,634 | 30 |
| 2013 · Form 990 | ||||||||
| $379,731,039 | $389,326,389 | $846,527,407 | $696,653,936 | $321,259,868 | $4,443,967 | $3,082,293 | 2,775 | 27 |
| 2012 · Form 990 | ||||||||
| $365,847,584 | $378,965,917 | $883,112,215 | $727,473,631 | $334,268,986 | $4,768,760 | $3,154,679 | 2,846 | 45 |
| 2011 · Form 990 | ||||||||
| $418,244,792 | $409,831,176 | $913,484,033 | $727,544,799 | $375,025,082 | $5,315,745 | $3,770,136 | 2,937 | 44 |
| 2010 · Form 990 | ||||||||
| $423,942,869 | $401,851,470 | $865,626,306 | $692,871,607 | $390,761,176 | $5,509,730 | $3,824,491 | 2,904 | 44 |
| 2009 · Form 990 | ||||||||
| $387,104,746 | $391,489,990 | $850,789,296 | $683,055,077 | $368,243,444 | $5,440,534 | $3,818,684 | 2,861 | 47 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- California Institute for BioMedical La Jolla, CA · 6 people in common (Claudia S Luttrell, Jared M Machado, Jing Li)
- CALIFORNIA HEALTHCARE INSTITUTE San Diego, CA · 2 people in common (Eric Topol, Peter C Farrell)
- THE BIOMEDICAL RESEARCH EDUCATION San Diego, CA · 2 people in common (John D Diekman, Peter G Schultz)
- FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC Rockville, MD · 1 person in common (Sherry Lansing)
Funders of this organization
249 grantors reported grants to this organization, $475,827,746 in all, tax years 2009 to 2025; the 25 largest shown (all 249). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Total given | Grants | Latest year's amount | Latest year | Years given | Type | Match | Grants |
|---|---|---|---|---|---|---|---|---|
| GATES FOUNDATION | $180,189,780 | 78 | $20,977,973 | 2024 | 2010-2011, 2014-2024 | Private foundation | Fuzzy filed as “SCRIPPS RESEARCH INSTITUTE”, “SCRIPPS RESEARCH INSTITUTE THE” | show |
| INTERNATIONAL AIDS VACCINE INITIATIVE INC | $34,992,601 | 17 | $2,460,785 | 2025 | 2010-2025 | Public charity | Exact | show |
| ALSAM FOUNDATION | $18,000,000 | 4 | $4,957,652 | 2023 | 2021-2023 | Private foundation | Fuzzy filed as “THE SCRIPPS RESEARCH INSTITUTE” | show |
| NORTHWESTERN UNIVERSITY | $14,718,105 | 16 | $1,248,379 | 2024 | 2009-2024 | DAF sponsor | Exact | show |
| CORNELL UNIVERSITY | $12,848,021 | 15 | $1,585,700 | 2024 | 2010-2015, 2017-2024 | Public charity | Exact | show |
| FREEDOM TOGETHER FOUNDATION | $8,438,500 | 12 | $750,000 | 2024 | 2014-2024 | Private foundation | Fuzzy filed as “SCRIPPS RESEARCH INSTITUTE”, “THE SCRIPPS RESEARCH INSTITUTE” | show |
| SCRIPPS FLORIDA FUNDING CORPORATION | $8,420,994 | 1 | $8,420,994 | 2012 | 2012 | Public charity | Exact | show |
| FIDELITY INVESTMENTS CHARITABLE GIFT FUND | $7,624,372 | 9 | $1,032,039 | 2024 | 2016-2024 | DAF sponsor | Exact | show |
| SEATTLE CHILDRENS HOSPITAL | $7,436,638 | 5 | $1,984,470 | 2024 | 2020-2024 | DAF sponsor | Exact | show |
| FRED HUTCHINSON CANCER CENTER | $7,319,628 | 2 | $390,273 | 2024 | 2023-2024 | Public charity | Exact | show |
| JOHN MARTIN FOUNDATION | $6,800,000 | 6 | $1,250,000 | 2025 | 2023-2025 | Private foundation | Fuzzy filed as “THE SCRIPPS RESEARCH INSTITUTE” | show |
| GATES PHILANTHROPY PARTNERS | $6,614,988 | 3 | $4,500,000 | 2021 | 2019-2021 | Public charity | Exact | show |
| CONRAD PREBYS FOUNDATION | $5,850,181 | 11 | $750,000 | 2024 | 2021-2024 | Private foundation | Fuzzy filed as “SCRIPPS RESEARCH INSTITUTE”, “THE SCRIPPS RESEARCH INSTITUTE” | show |
| EMORY UNIVERSITY | $5,460,927 | 16 | $76,268 | 2024 | 2009-2024 | Public charity | Exact | show |
| BETH ISRAEL DEACONESS MEDICAL CENTER INC | $5,193,595 | 11 | $133,519 | 2021 | 2011-2021 | Public charity | Exact | show |
| DONOR ADVISED CHARITABLE GIVING | $4,685,926 | 9 | $333,225 | 2024 | 2015-2016, 2018-2024 | DAF sponsor | Exact | show |
| VANDERBILT UNIVERSITY MEDICAL CENTER | $4,661,057 | 6 | $24,158 | 2020 | 2015-2020 | Public charity | Exact | show |
| AMERICAN HEART ASSOCIATION INC | $4,441,150 | 13 | $69,548 | 2024 | 2010-2017, 2020-2024 | Public charity | Exact | show |
| UNIVERSITY OF PITTSBURGH | $4,149,728 | 15 | $451,029 | 2024 | 2009-2011, 2013-2024 | Public charity | Exact | show |
| ADAM R SCRIPPS FOUNDATION | $4,131,666 | 7 | $2,218,333 | 2024 | 2023-2024 | Private foundation | Fuzzy filed as “Scripps Research Institute” | show |
| VANDERBILT UNIVERSITY | $3,989,754 | 7 | $2,519,368 | 2024 | 2009-2011, 2014-2015, 2023-2024 | DAF sponsor | Exact | show |
| UNIVERSITY OF MIAMI | $3,732,657 | 10 | $92,021 | 2020 | 2011-2020 | Public charity | Exact | show |
| ALZHEIMERS DRUG DISCOVERY FOUNDATION | $3,625,000 | 3 | $3,000,000 | 2022 | 2014, 2016, 2022 | Public charity | Exact | show |
| VANGUARD CHARITABLE ENDOWMENT PROGRAM | $3,575,656 | 5 | $1,142,356 | 2024 | 2020-2024 | DAF sponsor | Exact | show |
| THE DONALD E & DELIA B BAXTER FOUNDATION | $3,307,992 | 14 | $432,000 | 2025 | 2012-2025 | Private foundation | Fuzzy filed as “SCRIPPS RESEARCH INSTITUTE”, “THE SCRIPPS RESEARCH INSTITUTE” | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. NTEE: the IRS’s code when it lists one, otherwise FURP’s inferred code. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| JACKSON LABORATORY | ME | H92 | $652,542,607 | $617,013,316 | PRESIDENT & CEO | $2,746,750 | Same NTEE code H92, revenue within 2x |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | MA | H92 | $222,267,487 | $174,270,117 | DIRECTOR/PRESIDENT | $1,081,921 | Same NTEE code H92, revenue within 5x |
| HOWARD HUGHES MEDICAL INSTITUTE | MD | H92 | $2,004,784,057 | $1,178,202,544 | VP & CHIEF INVESTMENT OFFICER | $2,004,966 | Same NTEE code H92, revenue within 5x |
| SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | CA | H92 | $114,401,821 | $116,107,616 | CEO & PRESIDENT | $1,345,526 | Same NTEE code H92, revenue within 10x, same state |
| STOWERS INSTITUTE FOR MEDICAL RESEARCH | MO | H92 | $102,011,512 | $104,688,153 | DIRECTOR/CHAIR DECEASED 3/27/25 | $3,206,337 | Same NTEE code H92, revenue within 10x, similar name |
| LOVELACE BIOMEDICAL RESEARCH INSTITUTE | NM | H92 | $83,397,041 | $87,744,696 | PRESIDENT AND CHAIRMAN OF THE BOARD | $1,387,128 | Same NTEE code H92, revenue within 10x, similar name |
| BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | WA | H92 | $81,277,408 | $80,732,627 | CHIEF EXECUTIVE OFFICER VMFH | $5,754,859 | Same NTEE code H92, revenue within 10x |
| FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC | MD | H92 | $78,507,209 | $76,818,918 | Chief Executive Officer | $689,835 | Same NTEE code H92, revenue within 10x |
| OKLAHOMA MEDICAL RESEARCH FOUNDATION | OK | H92 | $136,776,829 | $126,476,987 | EVP and Chief Medical Officer | $1,016,574 | Same NTEE code H92, revenue within 10x |
| LIFESPAN RESEARCH INSTITUTION | CA | H92 | $1,799,122 | $6,520,518 | Chief Executive Officer | $292,427 | Same NTEE code H92, revenue differs more than 10x, same state, similar name |
| SOUTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION | CA | H92 | $2,941,163 | $2,335,904 | Chair | $419,756 | Same NTEE code H92, revenue differs more than 10x, same state |
| BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA | CA | H92 | $141,627 | $136,871 | PRESIDENT AND CEO | $29,482 | Same NTEE code H92, revenue differs more than 10x, same state |
| GENETIC INFORMATION RESEARCH INSTITUTE | CA | H92 | $617,227 | $490,110 | Trustee | $132,779 | Same NTEE code H92, revenue differs more than 10x, same state, similar name |
| GARY AND MARY WEST HEALTH INSTITUTE | CA | H92 | $44,564,569 | $42,453,440 | CMO & EVP CLINICAL RESEARCH | $958,995 | Same NTEE code H92, revenue differs more than 10x, same state |
| FOGARTY INSTITUTE FOR INNOVATION | CA | H92 | $2,887,855 | $7,841,457 | CHIEF STRATEGY OFFICER | $377,860 | Same NTEE code H92, revenue differs more than 10x, same state |
| APPLIED BIOMEDICAL SCIENCE INSTITUTE | CA | H92 | $4,539,463 | $4,281,826 | PROFESSOR | $223,011 | Same NTEE code H92, revenue differs more than 10x, same state |
| THE PANORAMA INSTITUTE OF MOLECULAR MEDICINE | CA | H92 | $65,313 | $42,054 | CHIEF EXECUTIVE OFFICER | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| AGOURON INSTITUTE | CA | H92 | $1,853,788 | $2,575,826 | SCIENTIST | $272,898 | Same NTEE code H92, revenue differs more than 10x, same state |
| CALIFORNIA SOCIETY FOR BIOMEDICAL RESEARCH | CA | H92 | $72,075 | $85,444 | Executive Direc | $36,360 | Same NTEE code H92, revenue differs more than 10x, same state |
| SERVAREGMP | CA | H92 | $2,328,476 | $2,353,600 | EXECUTIVE DIRECTOR | $182,850 | Same NTEE code H92, revenue differs more than 10x, same state |
| BIOMOLECULAR ULTRASOUND AND SONOGENETICS CONFERENCE ORG INC | CA | H92 | $123,888 | $102,655 | Secretary | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| PINEHURST BIOMEDICAL FOUNDATION | CA | H92 | $8 | $60,229 | CEO | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| RESMED SLEEP DISORDERED BREATHING FOUNDATION | CA | H92 | $1,216,507 | $732,430 | CHAIRMAN | $0 | Same NTEE code H92, revenue differs more than 10x, same state |
| STEADMAN PHILIPPON RESEARCH INSTITUTE | CO | H92 | $14,151,760 | $16,201,121 | CHIEF SCIENTIFIC OFFICER | $661,826 | Same NTEE code H92, revenue differs more than 10x, similar name |
| IMAGE GUIDED THERAPY RESEARCH INSTITUTE | MD | H92 | $77,000 | $76,708 | PRESIDENT | $0 | Same NTEE code H92, revenue differs more than 10x, similar name |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $537,453,981 spent · pay $202,849,110 · grants $117,089,363 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $159,222,303 | $139,711,560 | $14,944,012 | $4,566,731 | 29.6% | |
| Grants to US organizations and governments | $78,622,580 | $78,622,580 | - | - | 14.6% | |
| Fees: other services | $71,526,866 | $71,517,926 | - | $8,940 | 13.3% | |
| Other (as described) | LAB SUPPLIES | $47,869,678 | $47,869,678 | - | - | 8.9% |
| Other employee benefits | $30,926,845 | $27,208,513 | $2,969,939 | $748,393 | 5.8% | |
| Depreciation and depletion | $25,697,151 | $25,130,397 | $565,603 | $1,151 | 4.8% | |
| Grants outside the US | $20,997,755 | $20,997,755 | - | - | 3.9% | |
| Grants to US individuals | $17,469,028 | $17,469,028 | - | - | 3.3% | |
| Occupancy | $14,817,332 | $13,158,928 | $1,631,230 | $27,174 | 2.8% | |
| Other (as described) | UTILITIES | $13,496,441 | $13,149,298 | $141,783 | $205,360 | 2.5% |
| Payroll taxes | $12,313,027 | $10,579,526 | $1,428,088 | $305,413 | 2.3% | |
| Other (as described) | CONTRACTED SVCS - OTHER | $12,027,256 | $6,581,224 | $4,738,346 | $707,686 | 2.2% |
| Information technology | $8,516,546 | $4,852,023 | $3,485,279 | $179,244 | 1.6% | |
| Office expenses | $4,838,907 | $4,122,859 | $578,906 | $137,142 | 0.9% | |
| Pay: officers, directors, trustees, key employees | $4,814,094 | $966,243 | $3,781,745 | $66,106 | 0.9% | |
| Fees: legal | $4,252,665 | $3,524,240 | $717,600 | $10,825 | 0.8% | |
| Travel | $4,076,191 | $3,676,527 | $305,291 | $94,373 | 0.8% | |
| Interest | $3,817,254 | $3,817,254 | - | - | 0.7% | |
| Insurance | $2,345,785 | $2,311,732 | $34,053 | - | 0.4% | |
| Advertising and promotion | $1,922,372 | $1,256,739 | $62,437 | $603,196 | 0.4% | |
| Fees: investment management | $1,716,237 | $1,716,237 | - | - | 0.3% | |
| Fees: accounting | $594,827 | $31,507 | $563,320 | - | 0.1% | |
| Pension plan contributions | -$4,427,159 | -$3,815,456 | -$490,964 | -$120,739 | -0.8% | |
| Total | $537,453,981 | 100% |
2023 · Form 990 · $528,437,793 spent · pay $203,451,715 · grants $127,840,846 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $158,841,218 | $139,560,027 | $14,619,667 | $4,661,524 | 30.1% | |
| Grants to US organizations and governments | $93,978,151 | $93,978,151 | - | - | 17.8% | |
| Other (as described) | LAB SUPPLIES | $52,192,159 | $52,192,159 | $0 | $0 | 9.9% |
| Fees: other services | $38,650,950 | $36,809,234 | $1,820,111 | $21,605 | 7.3% | |
| Other employee benefits | $29,925,303 | $26,437,241 | $2,871,203 | $616,859 | 5.7% | |
| Depreciation and depletion | $26,556,631 | $26,002,743 | $552,737 | $1,151 | 5.0% | |
| Grants outside the US | $21,738,261 | $21,738,261 | - | - | 4.1% | |
| Other (as described) | CONTRACTED SVCS - OTHER | $14,730,775 | $8,695,645 | $5,010,954 | $1,024,176 | 2.8% |
| Occupancy | $14,540,937 | $7,745,534 | $6,776,219 | $19,184 | 2.8% | |
| Other (as described) | UTILITIES | $13,776,464 | $12,230,383 | $1,333,260 | $212,821 | 2.6% |
| Grants to US individuals | $12,124,434 | $12,124,434 | - | - | 2.3% | |
| Payroll taxes | $11,126,653 | $9,791,853 | $1,054,423 | $280,377 | 2.1% | |
| Information technology | $7,951,531 | $4,718,554 | $3,030,696 | $202,281 | 1.5% | |
| Fees: legal | $7,851,867 | $7,558,319 | $158,944 | $134,604 | 1.5% | |
| Office expenses | $5,443,265 | $4,461,681 | $777,704 | $203,880 | 1.0% | |
| Travel | $4,864,747 | $4,323,029 | $377,792 | $163,926 | 0.9% | |
| Pay: officers, directors, trustees, key employees | $4,444,304 | $534,559 | $3,822,452 | $87,293 | 0.8% | |
| Interest | $3,412,238 | $3,412,238 | - | - | 0.6% | |
| Advertising and promotion | $2,325,447 | $1,448,638 | $48,917 | $827,892 | 0.4% | |
| Insurance | $2,161,649 | $2,112,039 | $49,610 | - | 0.4% | |
| Fees: investment management | $1,527,223 | $1,527,223 | - | - | 0.3% | |
| Fees: accounting | $770,246 | $189,775 | $571,147 | $9,324 | 0.1% | |
| Fees: professional fundraisers | $389,103 | - | - | $389,103 | 0.1% | |
| Pension plan contributions | -$885,763 | -$763,679 | -$97,291 | -$24,793 | -0.2% | |
| Total | $528,437,793 | 100% |
2022 · Form 990 · $532,639,503 spent · pay $298,111,481 · grants $84,931,251 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $249,699,278 | $237,074,752 | $10,562,793 | $2,061,733 | 46.9% | |
| Grants to US organizations and governments | $69,477,912 | $69,477,912 | - | - | 13.0% | |
| Fees: other services | $57,839,753 | $54,217,185 | $2,946,549 | $676,019 | 10.9% | |
| Other employee benefits | $33,738,427 | $30,748,349 | $2,531,508 | $458,570 | 6.3% | |
| Depreciation and depletion | $22,576,425 | $22,576,425 | - | - | 4.2% | |
| Other (as described) | LAB SUPPLIES | $22,556,148 | $20,130,960 | $2,338,337 | $86,851 | 4.2% |
| Other (as described) | UTILITIES | $13,831,087 | $13,691,242 | $0 | $139,845 | 2.6% |
| Grants to US individuals | $12,475,350 | $12,475,350 | - | - | 2.3% | |
| Payroll taxes | $10,396,552 | $9,734,815 | $581,571 | $80,166 | 2.0% | |
| Other (as described) | CONTRACTED SVCS - OTHER | $9,996,075 | $5,419,625 | $3,677,417 | $899,033 | 1.9% |
| Occupancy | $8,780,671 | $7,111,670 | $1,652,945 | $16,056 | 1.6% | |
| Pay: officers, directors, trustees, key employees | $5,207,183 | $812,954 | $4,394,229 | - | 1.0% | |
| Travel | $5,192,696 | $4,895,179 | $202,123 | $95,394 | 1.0% | |
| Office expenses | $3,545,465 | $3,170,512 | $210,290 | $164,663 | 0.7% | |
| Grants outside the US | $2,977,989 | $2,977,989 | - | - | 0.6% | |
| Interest | $2,924,004 | $2,924,004 | - | - | 0.5% | |
| Insurance | $2,354,447 | $2,193,135 | $161,312 | - | 0.4% | |
| Pension plan contributions | -$929,959 | -$870,767 | -$52,021 | -$7,171 | -0.2% | |
| Total | $532,639,503 | 100% |
2021 · Form 990 · $884,961,642 spent · pay $238,179,882 · grants $467,412,781 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Grants to US organizations and governments | $451,905,079 | $451,905,079 | - | - | 51.1% | |
| Other salaries and wages | $200,952,685 | $183,507,489 | $15,429,870 | $2,015,326 | 22.7% | |
| Fees: other services | $48,732,787 | $45,623,842 | $1,979,512 | $1,129,433 | 5.5% | |
| Other (as described) | CONTRACTED SVCS - OTHER | $40,130,142 | $34,806,547 | $4,152,164 | $1,171,431 | 4.5% |
| Other employee benefits | $26,069,884 | $24,498,701 | $1,190,782 | $380,401 | 2.9% | |
| Depreciation and depletion | $25,761,485 | $25,759,046 | - | $2,439 | 2.9% | |
| Other (as described) | LAB SUPPLIES | $15,352,319 | $11,623,242 | $3,576,410 | $152,667 | 1.7% |
| Payroll taxes | $14,310,255 | $12,957,382 | $1,221,445 | $131,428 | 1.6% | |
| Grants to US individuals | $14,015,385 | $14,015,385 | - | - | 1.6% | |
| Other (as described) | UTILITIES | $11,324,332 | $10,965,653 | $0 | $358,679 | 1.3% |
| Occupancy | $9,772,979 | $7,617,417 | $2,155,337 | $225 | 1.1% | |
| Fees: legal | $8,308,743 | $8,308,743 | - | - | 0.9% | |
| Fees: management | $5,095,225 | $5,095,225 | - | - | 0.6% | |
| Interest | $4,993,554 | $4,993,554 | - | - | 0.6% | |
| Pay: officers, directors, trustees, key employees | $4,466,925 | $1,167,030 | $3,299,895 | - | 0.5% | |
| Office expenses | $3,546,335 | $3,214,975 | $174,275 | $157,085 | 0.4% | |
| Insurance | $3,021,755 | $2,253,415 | $5,466 | $762,874 | 0.3% | |
| Travel | $2,632,009 | $2,423,546 | $142,800 | $65,663 | 0.3% | |
| Grants outside the US | $1,492,317 | $1,492,317 | - | - | 0.2% | |
| Fees: accounting | $697,314 | $697,314 | - | - | 0.1% | |
| Pension plan contributions | -$7,619,867 | -$6,899,495 | -$650,390 | -$69,982 | -0.9% | |
| Total | $884,961,642 | 100% |
2020 · Form 990 · $473,843,953 spent · pay $217,363,929 · grants $82,523,976 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $178,350,856 | $167,148,638 | $9,436,581 | $1,765,637 | 37.6% | |
| Grants to US organizations and governments | $67,286,299 | $67,286,299 | - | - | 14.2% | |
| Fees: other services | $49,821,370 | $47,288,944 | $1,938,727 | $593,699 | 10.5% | |
| Other employee benefits | $32,002,278 | $30,163,324 | $1,478,894 | $360,060 | 6.8% | |
| Other (as described) | PROFESSIONAL SERVICES | $31,645,356 | $24,727,452 | $6,595,461 | $322,443 | 6.7% |
| Depreciation and depletion | $30,825,705 | $30,823,266 | - | $2,439 | 6.5% | |
| Other (as described) | LAB SUPPLIES | $30,546,781 | $27,323,052 | $3,065,619 | $158,110 | 6.4% |
| Grants to US individuals | $14,029,323 | $14,029,323 | - | - | 3.0% | |
| Payroll taxes | $13,130,600 | $12,125,960 | $887,042 | $117,598 | 2.8% | |
| Other (as described) | UTILITIES | $12,193,236 | $11,637,321 | - | $555,915 | 2.6% |
| Occupancy | $8,884,814 | $6,999,967 | $1,789,531 | $95,316 | 1.9% | |
| Pay: officers, directors, trustees, key employees | $4,764,214 | $882,637 | $3,881,577 | - | 1.0% | |
| Insurance | $3,622,938 | $2,855,066 | $5,522 | $762,350 | 0.8% | |
| Office expenses | $3,618,331 | $3,317,796 | $125,718 | $174,817 | 0.8% | |
| Interest | $1,897,469 | $1,897,469 | - | - | 0.4% | |
| Grants outside the US | $1,208,354 | $1,208,354 | - | - | 0.3% | |
| Travel | $900,048 | $862,781 | $33,768 | $3,499 | 0.2% | |
| Pension plan contributions | -$10,884,019 | -$10,051,267 | -$735,274 | -$97,478 | -2.3% | |
| Total | $473,843,953 | 100% |
2019 · Form 990 · $444,003,884 spent · pay $204,838,315 · grants $14,124,814 · events $20,024
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $157,591,254 | $147,027,300 | $8,466,946 | $2,097,008 | 35.5% | |
| Fees: other services | $111,149,780 | $108,677,347 | $1,804,064 | $668,369 | 25.0% | |
| Other employee benefits | $31,248,037 | $29,557,376 | $1,340,610 | $350,051 | 7.0% | |
| Depreciation and depletion | $29,510,230 | $29,506,601 | - | $3,629 | 6.6% | |
| Other (as described) | Lab Supplies | $29,489,608 | $25,467,113 | $3,855,958 | $166,537 | 6.6% |
| Other (as described) | Professional Services | $23,517,942 | $19,489,026 | $3,790,649 | $238,267 | 5.3% |
| Grants to US individuals | $13,012,232 | $13,012,232 | - | - | 2.9% | |
| Payroll taxes | $11,790,105 | $10,888,848 | $759,895 | $141,362 | 2.7% | |
| Other (as described) | Utilities | $11,241,949 | $10,691,657 | - | $550,292 | 2.5% |
| Occupancy | $10,149,756 | $8,443,842 | $1,613,466 | $92,448 | 2.3% | |
| Pay: officers, directors, trustees, key employees | $4,294,526 | $1,488,956 | $2,805,570 | - | 1.0% | |
| Office expenses | $3,261,626 | $2,917,403 | $156,637 | $187,586 | 0.7% | |
| Insurance | $3,114,435 | $2,318,440 | $4,991 | $791,004 | 0.7% | |
| Travel | $2,446,145 | $2,311,450 | $94,680 | $40,015 | 0.6% | |
| Interest | $2,019,208 | $2,019,208 | - | - | 0.5% | |
| Grants outside the US | $1,112,582 | $1,112,582 | - | - | 0.3% | |
| Fees: lobbying | $10,482 | $10,482 | - | - | 0.0% | |
| Fees: professional fundraisers | $2,492 | - | - | $2,492 | 0.0% | |
| Pension plan contributions | -$85,607 | -$79,063 | -$5,518 | -$1,026 | -0.0% | |
| Other (as described) | Disposal of Equipment | -$134,194 | -$134,194 | - | - | -0.0% |
| All other expenses | -$738,704 | - | - | -$738,704 | -0.2% | |
| Fundraising events Event | direct expenses; gross income $20,024 | $20,024 | reported apart | |||
| Total | $444,003,884 | 100% |
2018 · Form 990 · $432,597,967 spent · pay $200,866,661 · grants $15,022,351 · events $38,951
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $143,278,684 | $133,837,000 | $7,468,755 | $1,972,929 | 33.1% | |
| Fees: other services | $98,825,860 | $96,022,814 | $2,663,930 | $139,116 | 22.8% | |
| Other employee benefits | $36,487,647 | $34,047,793 | $2,107,313 | $332,541 | 8.4% | |
| Depreciation and depletion | $31,480,693 | $31,448,863 | $9,629 | $22,201 | 7.3% | |
| Other (as described) | Lab Supplies | $29,804,726 | $27,133,082 | $2,486,510 | $185,134 | 6.9% |
| Occupancy | $22,654,465 | $21,025,231 | $1,573,925 | $55,309 | 5.2% | |
| Other (as described) | Utilities | $13,777,896 | $13,226,508 | $47,571 | $503,817 | 3.2% |
| Grants to US individuals | $13,030,451 | $13,030,451 | - | - | 3.0% | |
| Other (as described) | Professional Services | $10,497,622 | $7,684,733 | $2,429,795 | $383,094 | 2.4% |
| Payroll taxes | $8,685,333 | $8,035,271 | $543,193 | $106,869 | 2.0% | |
| Pension plan contributions | $8,382,986 | $7,755,553 | $524,284 | $103,149 | 1.9% | |
| Travel | $4,382,688 | $4,085,861 | $171,664 | $125,163 | 1.0% | |
| Pay: officers, directors, trustees, key employees | $4,032,011 | $1,472,798 | $2,559,213 | - | 0.9% | |
| Office expenses | $4,001,206 | $3,367,820 | $483,788 | $149,598 | 0.9% | |
| Insurance | $3,173,421 | $2,187,190 | $115,856 | $870,375 | 0.7% | |
| Grants outside the US | $1,991,900 | $1,991,900 | - | - | 0.5% | |
| Interest | $1,513,716 | $1,513,716 | - | - | 0.3% | |
| Fees: lobbying | $59,596 | $59,596 | - | - | 0.0% | |
| Fees: professional fundraisers | $52,468 | - | - | $52,468 | 0.0% | |
| Other (as described) | Rental Services | -$1,050,525 | - | - | -$1,050,525 | -0.2% |
| All other expenses | -$2,464,877 | -$2,464,877 | - | - | -0.6% | |
| Fundraising events Event | direct expenses; gross income $38,951 | $38,951 | reported apart | |||
| Total | $432,597,967 | 100% |
2017 · Form 990 · $373,107,791 spent · pay $150,123,705 · grants $15,511,633 · events $47,893
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $116,872,260 | $112,989,333 | $2,456,856 | $1,426,071 | 31.3% | |
| Fees: other services | $82,244,931 | $79,310,161 | $2,613,095 | $321,675 | 22.0% | |
| Other (as described) | Lab Supplies | $32,496,087 | $30,983,122 | $1,385,022 | $127,943 | 8.7% |
| Depreciation and depletion | $31,566,074 | $31,433,071 | - | $133,003 | 8.5% | |
| Other employee benefits | $28,552,667 | $27,102,949 | $1,270,546 | $179,172 | 7.7% | |
| Occupancy | $21,099,534 | $20,146,238 | $896,298 | $56,998 | 5.7% | |
| Other (as described) | Utilities | $15,113,777 | $14,584,418 | - | $529,359 | 4.1% |
| Other (as described) | Professional Services | $14,387,685 | $12,338,254 | $1,495,647 | $553,784 | 3.9% |
| Grants to US individuals | $12,180,160 | $12,180,160 | - | - | 3.3% | |
| Payroll taxes | $8,108,107 | $7,664,167 | $357,454 | $86,486 | 2.2% | |
| Pay: officers, directors, trustees, key employees | $4,642,511 | $1,205,290 | $3,437,221 | - | 1.2% | |
| Travel | $3,517,449 | $3,324,984 | $91,319 | $101,146 | 0.9% | |
| Grants outside the US | $3,331,473 | $3,331,473 | - | - | 0.9% | |
| Office expenses | $3,270,152 | $2,980,257 | $141,321 | $148,574 | 0.9% | |
| Insurance | $3,149,931 | $2,568,976 | $23,306 | $557,649 | 0.8% | |
| Interest | $1,200,591 | $1,200,591 | - | - | 0.3% | |
| Other (as described) | Disposal of Equipment | $581,840 | $581,840 | - | - | 0.2% |
| Fees: professional fundraisers | $202,426 | - | - | $202,426 | 0.1% | |
| Fees: lobbying | $61,997 | $61,997 | - | - | 0.0% | |
| All other expenses | -$1,420,021 | - | - | -$1,420,021 | -0.4% | |
| Pension plan contributions | -$8,051,840 | -$7,610,980 | -$354,974 | -$85,886 | -2.2% | |
| Fundraising events Event | direct expenses; gross income $47,893 | $47,893 | reported apart | |||
| Total | $373,107,791 | 100% |
2016 · Form 990 · $366,352,436 spent · pay $156,817,945 · grants $15,071,691 · events $71,464
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $119,325,099 | $113,584,968 | $4,900,976 | $839,155 | 32.6% | |
| Fees: other services | $76,107,083 | $73,140,405 | $2,601,733 | $364,945 | 20.8% | |
| Other (as described) | Lab Supplies | $32,317,897 | $30,676,614 | $1,363,295 | $277,988 | 8.8% |
| Depreciation and depletion | $31,289,185 | $31,158,622 | - | $130,563 | 8.5% | |
| Other employee benefits | $27,939,390 | $27,045,667 | $812,875 | $80,848 | 7.6% | |
| Occupancy | $19,018,299 | $18,089,354 | $864,355 | $64,590 | 5.2% | |
| Other (as described) | Utilities | $14,235,728 | $13,727,890 | $0 | $507,838 | 3.9% |
| Grants to US individuals | $11,340,328 | $11,340,328 | - | - | 3.1% | |
| Other (as described) | Professional Services | $10,899,473 | $8,599,984 | $1,900,397 | $399,092 | 3.0% |
| Payroll taxes | $8,086,564 | $7,625,988 | $409,756 | $50,820 | 2.2% | |
| Grants outside the US | $3,731,363 | $3,731,363 | - | - | 1.0% | |
| Insurance | $3,534,458 | $2,855,421 | $9,865 | $669,172 | 1.0% | |
| Travel | $3,330,598 | $3,244,286 | $53,645 | $32,667 | 0.9% | |
| Office expenses | $3,055,775 | $2,749,945 | $120,172 | $185,658 | 0.8% | |
| Pay: officers, directors, trustees, key employees | $2,861,354 | $996,361 | $1,864,993 | - | 0.8% | |
| Interest | $1,244,780 | $1,244,780 | - | - | 0.3% | |
| All other expenses | $696,993 | $696,993 | - | - | 0.2% | |
| Fees: lobbying | $184,542 | $184,542 | - | - | 0.1% | |
| Fees: professional fundraisers | $115,752 | - | - | $115,752 | 0.0% | |
| Pension plan contributions | -$1,394,462 | -$1,315,039 | -$70,659 | -$8,764 | -0.4% | |
| Other (as described) | Rental Expenses | -$1,567,763 | - | - | -$1,567,763 | -0.4% |
| Fundraising events Event | direct expenses; gross income $71,464 | $71,464 | reported apart | |||
| Total | $366,352,436 | 100% |
2015 · Form 990 · $364,687,971 spent · pay $166,464,708 · grants $15,779,618 · events $53,891
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $121,159,701 | $115,919,277 | $3,582,455 | $1,657,969 | 33.2% | |
| Fees: other services | $63,179,901 | $60,102,455 | $2,518,891 | $558,555 | 17.3% | |
| Other (as described) | Lab Supplies | $34,607,727 | $32,565,435 | $1,781,514 | $260,778 | 9.5% |
| Depreciation and depletion | $32,343,053 | $32,212,490 | - | $130,563 | 8.9% | |
| Other employee benefits | $25,679,324 | $24,738,094 | $754,202 | $187,028 | 7.0% | |
| Occupancy | $19,252,085 | $18,437,551 | $755,575 | $58,959 | 5.3% | |
| Other (as described) | Utilities | $14,178,070 | $13,687,629 | $0 | $490,441 | 3.9% |
| Grants to US individuals | $11,076,107 | $11,076,107 | - | - | 3.0% | |
| Other (as described) | Professional Services | $9,232,961 | $7,639,953 | $1,324,506 | $268,502 | 2.5% |
| Payroll taxes | $8,519,864 | $7,975,940 | $441,295 | $102,629 | 2.3% | |
| Pension plan contributions | $5,703,992 | $5,339,838 | $295,444 | $68,710 | 1.6% | |
| Pay: officers, directors, trustees, key employees | $5,401,827 | $1,855,194 | $3,546,633 | - | 1.5% | |
| Grants outside the US | $4,703,511 | $4,703,511 | - | - | 1.3% | |
| Insurance | $3,204,991 | $2,891,675 | $312,316 | $1,000 | 0.9% | |
| Travel | $3,129,087 | $3,008,673 | $36,136 | $84,278 | 0.9% | |
| Interest | $2,968,320 | $2,968,320 | - | - | 0.8% | |
| Office expenses | $2,848,914 | $2,591,297 | $92,992 | $164,625 | 0.8% | |
| Fees: lobbying | $172,388 | $172,388 | - | - | 0.0% | |
| Fees: professional fundraisers | $112,867 | - | - | $112,867 | 0.0% | |
| Other (as described) | RENTAL EXPENSES | -$1,340,902 | - | - | -$1,340,902 | -0.4% |
| All other expenses | -$1,445,817 | -$1,445,817 | - | - | -0.4% | |
| Fundraising events Event | direct expenses; gross income $53,891 | $53,891 | reported apart | |||
| Total | $364,687,971 | 100% |
2014 · Form 990 · $382,942,496 spent · pay $171,574,144 · grants $13,848,564 · events $60,748
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $125,057,412 | $119,412,677 | $3,848,490 | $1,796,245 | 32.7% | |
| Fees: other services | $66,010,732 | $62,981,233 | $2,606,169 | $423,330 | 17.2% | |
| Other (as described) | LAB SUPPLIES | $36,629,784 | $35,201,016 | $1,186,912 | $241,856 | 9.6% |
| Depreciation and depletion | $32,448,693 | $32,308,612 | - | $140,081 | 8.5% | |
| Other employee benefits | $26,045,134 | $25,359,950 | $496,202 | $188,982 | 6.8% | |
| Occupancy | $22,915,658 | $21,994,374 | $848,846 | $72,438 | 6.0% | |
| Other (as described) | UTILITIES | $15,532,287 | $15,041,057 | $0 | $491,230 | 4.1% |
| Other (as described) | PROFESSIONAL SERVICES | $14,022,731 | $12,484,960 | $1,387,784 | $149,987 | 3.7% |
| Grants to US individuals | $8,955,703 | $8,955,703 | - | - | 2.3% | |
| Payroll taxes | $8,746,748 | $8,177,428 | $455,668 | $113,652 | 2.3% | |
| Pension plan contributions | $7,497,017 | $7,009,042 | $390,562 | $97,413 | 2.0% | |
| Pay: officers, directors, trustees, key employees | $4,227,833 | $874,568 | $3,353,265 | - | 1.1% | |
| Grants outside the US | $4,142,861 | $4,142,861 | - | - | 1.1% | |
| Travel | $3,806,120 | $3,671,069 | $44,762 | $90,289 | 1.0% | |
| Insurance | $3,367,732 | $3,365,179 | $868 | $1,685 | 0.9% | |
| Office expenses | $2,785,344 | $2,532,315 | $92,774 | $160,255 | 0.7% | |
| Interest | $2,058,273 | $2,058,273 | - | - | 0.5% | |
| Grants to US organizations and governments | $750,000 | $750,000 | - | - | 0.2% | |
| Fees: professional fundraisers | $223,267 | - | - | $223,267 | 0.1% | |
| Fees: lobbying | $110,979 | $110,979 | - | - | 0.0% | |
| Other (as described) | DISP OF EQUIP & OTHER | -$2,391,812 | -$1,350,734 | $0 | -$1,041,078 | -0.6% |
| Fundraising events Event | direct expenses; gross income $60,748 | $60,748 | reported apart | |||
| Total | $382,942,496 | 100% |
2013 · Form 990 · $389,326,389 spent · pay $187,814,675 · grants $8,745,844 · events $179,180
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $136,696,769 | $129,710,677 | $5,053,059 | $1,933,033 | 35.1% | |
| Fees: other services | $63,609,295 | $59,944,522 | $3,244,560 | $420,213 | 16.3% | |
| Other (as described) | LAB SUPPLIES | $37,025,133 | $35,123,561 | $1,602,662 | $298,910 | 9.5% |
| Depreciation and depletion | $33,119,506 | $33,005,293 | - | $114,213 | 8.5% | |
| Other employee benefits | $30,298,126 | $29,147,124 | $927,264 | $223,738 | 7.8% | |
| Occupancy | $24,081,867 | $22,775,824 | $1,216,324 | $89,719 | 6.2% | |
| Other (as described) | UTILITIES | $14,828,666 | $14,391,112 | - | $437,554 | 3.8% |
| Pension plan contributions | $10,848,130 | $10,150,750 | $542,406 | $154,974 | 2.8% | |
| Other (as described) | PROFESSIONAL SERVICES | $9,632,333 | $7,903,337 | $1,497,335 | $231,661 | 2.5% |
| Grants to US individuals | $8,236,672 | $8,236,672 | - | - | 2.1% | |
| Payroll taxes | $6,889,357 | $6,458,546 | $335,536 | $95,275 | 1.8% | |
| Insurance | $3,687,517 | $3,693,881 | -$7,334 | $970 | 0.9% | |
| Travel | $3,511,310 | $3,340,048 | $57,871 | $113,391 | 0.9% | |
| Pay: officers, directors, trustees, key employees | $3,082,293 | $1,327,613 | $1,754,680 | - | 0.8% | |
| Office expenses | $2,741,753 | $2,516,515 | $77,618 | $147,620 | 0.7% | |
| Interest | $2,177,208 | $2,177,208 | - | - | 0.6% | |
| Grants outside the US | $509,172 | $509,172 | - | - | 0.1% | |
| Fees: professional fundraisers | $184,484 | - | - | $184,484 | 0.0% | |
| Fees: lobbying | $93,773 | $93,773 | - | - | 0.0% | |
| Other (as described) | RENTAL EXPENSES | -$1,926,975 | -$1,107,697 | - | -$819,278 | -0.5% |
| Fundraising events Event | direct expenses; gross income $179,180 | $179,180 | reported apart | |||
| Total | $389,326,389 | 100% |
2012 · Form 990 · $378,965,917 spent · pay $171,810,363 · grants $6,890,395 · events $82,330
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $141,996,803 | $135,177,498 | $5,402,850 | $1,416,455 | 37.5% | |
| Office expenses | $59,050,259 | $58,613,208 | $365,874 | $71,177 | 15.6% | |
| Fees: other services | $57,006,766 | $50,435,933 | $5,899,771 | $671,062 | 15.0% | |
| Depreciation and depletion | $34,404,976 | $34,179,135 | $205,846 | $19,995 | 9.1% | |
| Occupancy | $25,388,739 | $24,052,637 | $1,241,306 | $94,796 | 6.7% | |
| Other (as described) | UTILITIES | $13,470,480 | $13,025,775 | $391,376 | $53,329 | 3.6% |
| Pension plan contributions | $9,253,911 | $8,642,585 | $536,168 | $75,158 | 2.4% | |
| Payroll taxes | $9,187,317 | $8,431,724 | $637,592 | $118,001 | 2.4% | |
| Other employee benefits | $8,217,653 | $7,809,384 | $303,368 | $104,901 | 2.2% | |
| Grants to US individuals | $6,510,000 | $6,510,000 | - | - | 1.7% | |
| Travel | $3,519,913 | $3,367,230 | $54,742 | $97,941 | 0.9% | |
| Insurance | $3,323,508 | $2,283,252 | $1,036,291 | $3,965 | 0.9% | |
| Pay: officers, directors, trustees, key employees | $3,154,679 | $832,056 | $2,322,623 | - | 0.8% | |
| Interest | $2,289,355 | $2,289,355 | - | - | 0.6% | |
| Other (as described) | EQUIPMENT DISPOSALS | $929,655 | $929,655 | - | - | 0.2% |
| Other (as described) | PUBLICATIONS | $434,395 | $329,766 | $78,341 | $26,288 | 0.1% |
| Grants outside the US | $380,395 | $380,395 | - | - | 0.1% | |
| Other (as described) | LICENSES AND TAXES | $231,565 | $229,604 | $947 | $1,014 | 0.1% |
| Fees: professional fundraisers | $174,309 | - | - | $174,309 | 0.0% | |
| All other expenses | $28,424 | $28,424 | - | - | 0.0% | |
| Fees: lobbying | $12,815 | $126 | $12,689 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $82,330 | reported apart | |||
| Total | $378,965,917 | 100% |
2011 · Form 990 · $409,831,176 spent · pay $202,806,421 · grants $6,690,799 · events $214,726
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $141,881,196 | $136,160,463 | $4,585,204 | $1,135,529 | 34.6% | |
| Office expenses | $61,019,038 | $60,608,685 | $328,999 | $81,354 | 14.9% | |
| Fees: other services | $53,345,635 | $47,255,636 | $5,662,086 | $427,913 | 13.0% | |
| Other employee benefits | $39,662,782 | $39,086,875 | $481,588 | $94,319 | 9.7% | |
| Depreciation and depletion | $36,282,671 | $36,125,634 | $137,042 | $19,995 | 8.9% | |
| Occupancy | $25,290,205 | $23,980,476 | $1,214,917 | $94,812 | 6.2% | |
| Other (as described) | UTILITIES | $13,169,689 | $13,070,843 | $47,971 | $50,875 | 3.2% |
| Payroll taxes | $8,850,708 | $8,264,015 | $501,738 | $84,955 | 2.2% | |
| Pension plan contributions | $8,641,599 | $8,052,219 | $515,443 | $73,937 | 2.1% | |
| Grants to US individuals | $6,090,000 | $6,090,000 | - | - | 1.5% | |
| Travel | $3,777,590 | $3,625,781 | $99,629 | $52,180 | 0.9% | |
| Pay: officers, directors, trustees, key employees | $3,770,136 | $1,236,586 | $2,533,550 | - | 0.9% | |
| Insurance | $3,153,981 | $2,695,301 | $455,078 | $3,602 | 0.8% | |
| Interest | $2,392,025 | $2,392,025 | - | - | 0.6% | |
| Other (as described) | EQUIPMENT DISPOSALS | $1,041,173 | $1,041,173 | $0 | $0 | 0.3% |
| Grants outside the US | $600,799 | $600,799 | - | - | 0.1% | |
| Other (as described) | PUBLICATIONS | $526,151 | $394,516 | $124,088 | $7,547 | 0.1% |
| Other (as described) | LICENSES AND TAXES | $136,568 | $107,064 | $28,915 | $589 | 0.0% |
| Fees: professional fundraisers | $135,151 | - | - | $135,151 | 0.0% | |
| All other expenses | $60,029 | $60,029 | - | - | 0.0% | |
| Fees: lobbying | $4,050 | $1,080 | $2,970 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $214,726 | reported apart | |||
| Total | $409,831,176 | 100% |
2010 · Form 990 · $401,851,470 spent · pay $192,593,572 · grants $9,252,225 · events $28,966
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $143,680,424 | $137,318,746 | $4,991,663 | $1,370,015 | 35.8% | |
| Office expenses | $67,134,268 | $66,560,420 | $509,316 | $64,532 | 16.7% | |
| Fees: other services | $46,607,535 | $40,235,580 | $6,000,037 | $371,918 | 11.6% | |
| Depreciation and depletion | $36,175,138 | $36,004,064 | $151,233 | $19,841 | 9.0% | |
| Other employee benefits | $27,214,017 | $26,771,312 | $350,273 | $92,432 | 6.8% | |
| Occupancy | $25,279,405 | $24,027,348 | $1,158,124 | $93,933 | 6.3% | |
| Other (as described) | UTILITIES | $13,557,656 | $13,457,915 | $47,616 | $52,125 | 3.4% |
| Payroll taxes | $9,366,480 | $8,674,999 | $582,616 | $108,865 | 2.3% | |
| Pension plan contributions | $8,508,160 | $7,919,882 | $478,308 | $109,970 | 2.1% | |
| Grants to US individuals | $7,395,000 | $7,395,000 | - | - | 1.8% | |
| Travel | $4,270,751 | $4,102,700 | $102,648 | $65,403 | 1.1% | |
| Pay: officers, directors, trustees, key employees | $3,824,491 | $1,376,234 | $2,448,257 | - | 1.0% | |
| Insurance | $3,290,158 | $2,356,961 | $928,800 | $4,397 | 0.8% | |
| Interest | $2,477,814 | $2,477,814 | - | - | 0.6% | |
| Grants to US organizations and governments | $1,400,000 | $1,400,000 | - | - | 0.3% | |
| Grants outside the US | $457,225 | $457,225 | - | - | 0.1% | |
| All other expenses | $454,846 | $454,846 | - | - | 0.1% | |
| Other (as described) | PUBLICATIONS | $435,413 | $323,587 | $99,040 | $12,786 | 0.1% |
| Fees: professional fundraisers | $212,371 | - | - | $212,371 | 0.1% | |
| Other (as described) | LICENSES AND TAXES | $106,814 | $112,866 | -$6,155 | $103 | 0.0% |
| Fees: lobbying | $3,504 | $534 | $2,970 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $28,966 | reported apart | |||
| Total | $401,851,470 | 100% |
2009 · Form 990 · $391,489,990 spent · pay $188,196,176 · grants $7,538,338 · events $81,028
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $138,269,196 | $130,569,636 | $6,033,669 | $1,665,891 | 35.3% | |
| Office expenses | $68,834,800 | $68,305,439 | $412,583 | $116,778 | 17.6% | |
| Fees: other services | $42,597,312 | $35,671,376 | $6,654,257 | $271,679 | 10.9% | |
| Depreciation and depletion | $34,971,010 | $34,722,516 | $232,015 | $16,479 | 8.9% | |
| Other employee benefits | $28,757,707 | $28,096,381 | $564,053 | $97,273 | 7.3% | |
| Occupancy | $24,619,724 | $23,246,287 | $1,284,626 | $88,811 | 6.3% | |
| Other (as described) | Utilities | $13,790,089 | $13,722,938 | $48,184 | $18,967 | 3.5% |
| Payroll taxes | $9,120,740 | $8,508,147 | $515,110 | $97,483 | 2.3% | |
| Pension plan contributions | $8,229,849 | $7,631,523 | $442,197 | $156,129 | 2.1% | |
| Grants to US individuals | $7,084,000 | $7,084,000 | - | - | 1.8% | |
| Pay: officers, directors, trustees, key employees | $3,818,684 | $1,375,323 | $2,443,361 | - | 1.0% | |
| Insurance | $3,424,290 | $2,425,301 | $994,139 | $4,850 | 0.9% | |
| Travel | $3,362,623 | $3,243,541 | $60,182 | $58,900 | 0.9% | |
| Interest | $2,634,194 | $2,634,194 | - | - | 0.7% | |
| All other expenses | $963,620 | $963,620 | - | - | 0.2% | |
| Grants outside the US | $454,338 | $454,338 | - | - | 0.1% | |
| Other (as described) | Publications | $361,637 | $260,065 | $92,120 | $9,452 | 0.1% |
| Fees: professional fundraisers | $180,000 | - | - | $180,000 | 0.0% | |
| Other (as described) | Licenses and Taxes | $13,920 | $103,393 | -$90,932 | $1,459 | 0.0% |
| Fees: lobbying | $2,257 | $1,828 | $429 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $81,028 | reported apart | |||
| Total | $391,489,990 | 100% |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2027 | -$708 | $0 | 1 |
| 2026 | $162,419,399 | $1,818,959 | 273 |
| 2025 | $166,365,720 | $1,999,454 | 266 |
| 2024 | $160,530,671 | $2,206,312 | 280 |
| 2023 | $221,973,062 | $0 | 273 |
| 2022 | $290,197,279 | $2,545,376 | 280 |
| 2021 | $210,279,586 | $0 | 303 |
| 2020 | $180,188,474 | $2,467,614 | 291 |
| 2019 | $195,437,204 | $116,199 | 315 |
| 2018 | $196,062,468 | $1,472,517 | 342 |
| 2017 | $161,079,311 | $1,758,977 | 337 |
| 2016 | $254,667,751 | $3,077,877 | 380 |
| 2015 | $208,038,509 | $193,391 | 362 |
| 2014 | $223,414,118 | $1,420,165 | 385 |
| 2013 | $231,826,780 | $1,344,537 | 416 |
| 2012 | $252,399,584 | $1,148,714 | 453 |
| 2011 | $228,919,201 | $13,376,625 | 454 |
| 2010 | $256,009,838 | $12,132,023 | 497 |
| 2009 | $257,323,638 | $8,480,997 | 496 |
| 2008 | $114,217,198 | $4,141,059 | 274 |
| 2007 | $147,640,076 | $20,613,278 | 318 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2027 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | FOXO TRANSCRIPTION FACTORS AS CRITICAL REGULATORS OF INTERVERTEBRAL DISC AGING | -$708 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CENTER FOR ANTIVIRAL MEDICINES & PANDEMIC PREPAREDNESS (CAMPP) - SUMMARY THE ONGOING COVID-19 PANDEMIC HAS BROUGHT TO LIGHT AN URGENT NEED TO ENHANCE THE THERAP | $16,901,726 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | SCRIPPS CLINICAL AND TRANSLATIONAL SCIENCE HUB - PROJECT SUMMARY / ABSTRACT THE SCRIPPS RESEARCH TRANSLATIONAL INSTITUTE (SRTI) IS THE FOUNDATION FOR THE SCRIPP | $6,074,495 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | REVERSING IMMUNE DYSFUNCTION FOR HIV-1 ERADICATION - PROJECT SUMMARY ALTHOUGH THE RATE OF NEW HIV INFECTIONS HAS DECREASED, CONTAINMENT AND EVENTUAL ERADICATION | $4,958,401 |
| 2026 | National Science Foundation | Grant or other assistance | TECHNOLOGY, INNOVATION, AND PARTNERSHIPS 47.084 | NSF PCL-TEST BED: TOWARDS A GENERAL PLATFORM FOR AI-DRIVEN HIGH-THROUGHPUT REACTION DISCOVERY AND AUTOMATION -NSF PCL-TEST BED: TOWARDS A GENERAL PLATFORM FOR A | $4,873,120 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SELF-ASSEMBLING PROTEIN NANOPARTICLES PRESENTING STABILIZED HEMAGGLUTININ, NEURAMINIDASE, AND M2E ANTIGENS FOR UNIVERSAL INFLUENZA VACCINE DEVELOPMENT - PROJECT | $3,679,976 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PLANB2CUREHIV (THE 'PLANB' CONSORTIUM) - PROJECT SUMMARY ANTIBODIES CAPABLE OF NEUTRALIZING THE GLOBAL DIVERSITY OF HIV STRAINS ARE DIFFICULT TO ELICIT IN HUMAN | $3,479,555 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CENTER FOR RATIONAL HCV VACCINE DESIGN & EVALUATION - OVERALL PROJECT SUMMARY HEPATITIS C VIRUS (HCV) INFECTS OVER 50 MILLION PEOPLE WORLDWIDE AND REMAINS A LEA | $3,282,170 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR VIRAL SYSTEMS BIOLOGY (CVISB) | $2,971,268 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | BUILDING A SOMATOSENSORY ATLAS FOR INTEROCEPTION - PROJECT SUMMARY/ABSTRACT SOMATOSENSORY NEURONS ARE WELL-KNOWN FOR INNERVATING SKIN AND MUSCLE AND TRANSMITTIN | $2,847,421 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BROADLY EFFECTIVE HCV VACCINE - PROGRAM SUMMARY THE OVERARCHING GOAL OF THIS P01 PROPOSAL IS TO DEVELOP NOVEL HEPATITIS C VIRUS (HCV) VACCINE CANDIDATES THAT CA | $2,111,046 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MULTIDIMENSIONAL DEVELOPMENT OF HIGH-AFFINITY ANTI-GLYCAN ANTIBODIES TO FIGHT DEADLY BACTERIAL INFECTIONS - ABSTRACT THE DEVELOPMENT OF IMMUNOTHERAPIES FOCUSED | $1,961,391 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | CNS EFFECTS OF ALCOHOL: CELLULAR NEUROBIOLOGY | $1,856,533 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | INVESTIGATING DNA POLYMERASE O IN REPLICATION STRESS AND CANCER THERAPY - PRINCIPAL INVESTIGATOR: WU, XIAOHUA PROJECT SUMMARY REPLICATION STRESS OFTEN OCCURS W | $1,831,863 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | RATIONAL SYSTEMIC CHARACTERIZATION AND SELECTION OF ADJUVANTS FOR HIV VACCINE CANDIDATES (R-CASA) | $1,818,959 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE MULTI-OMICS VACCINE EVALUATION (MOVE) CONSORTIUM - PROJECT SUMMARY AN HIV VACCINE REPRESENTS OUR BEST OPPORTUNITY FOR ELICITING DURABLE, PROTECTIVE IMMUNITY | $1,796,659 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | DOGSURF: DATABASE OPTIMIZED FOR GRAPH SEARCH USING ROBUST FEDERATION - ABSTRACT THE TRANSLATOR PROJECT HAS MADE SUBSTANTIAL PROGRESS IN THE AREA OF BIOMEDICAL D | $1,746,403 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING THE POLYMERASE AND ENDONUCLEASE ACTIVITIES OF THE L PROTEIN OF HUMAN PATHOGENIC MAMMARENAVIRUSES - PROJECT SUMMARY SEVERAL MAMMARENAVIRUSES (MAAV), CH | $1,620,145 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | INTRACELLULAR TRAFFICKING OF THE ESSENTIAL SIGNALING METABOLITE HEME IN MYELOID CELLS: IMPACT ON PHYSIOLOGY AND DISEASE - THE GROWTH FACTORS AND TRANSCRIPTIONAL | $1,496,217 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | IMPACTING CELL GROWTH THROUGH ALTERED CIRCADIAN PROTEOLYSIS | $1,388,976 |
| 2026 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | PREDICTIVE MODELING OF VIRAL RNA CELLULAR BEHAVIOR - PROJECT SUMMARY/ABSTRACT MODERN BIOMEDICAL SCIENCE ENJOYS AN UNPRECEDENTED ABILITY TO IDENTIFY AND DESCRIBE | $1,380,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ENGINEERING DURABLE IMMUNITY BY OPTIMIZING HIV VACCINE PARAMETERS TO DRIVE LONG-LIVED PLASMA CELL DEVELOPMENT - PROJECT SUMMARY THE HIV PANDEMIC HAS BEEN RAGING | $1,379,954 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | SINGLE NUCLEUS GENE EXPRESSION IN MODERATE AND COMPULSIVE OPIOID SELF-ADMINISTRATION IN A RODENT MODEL OF HIV - SUMMARY THE ABUSE OF OPIOID DRUGS IS ASSOCIATED | $1,348,437 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ENHANCING DURABILITY OF V3 GLYCAN VACCINE RESPONSES IN RHESUS MACAQUES - ABSTRACT DEVELOPING AN HIV VACCINE CAPABLE OF ELICITING A DURABLE BROADLY NEUTRALIZING | $1,242,204 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | STUDYING THE MECHANISMS OF INITIATION AND PROGRESSION OF BETA CELL DEATH IN T1D - THE PROGRESS OF TYPE 1 DIABETES RESEARCH HAS BEEN LIMITED BY THE ACCESSIBILITY | $1,203,561 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ENGINEERING FUNCTIONALLY ADDRESSABLE DIRECT-ACTING THROMBOLYTIC ENZYMES - PROJECT SUMMARY/ABSTRACT THE DEVELOPMENT OF PLASMINOGEN ACTIVATORS (PAS) REVOLUTIONIZ | $1,101,338 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GERMLINE-TARGETED VACCINES USING MEMBRANE ENV LIPOSOMES TO ELICIT HIV-1 MPER BNABS - SUMMARY AN HIV/AIDS VACCINE WILL LIKELY NEED TO ELICIT BROADLY NEUTRALIZING | $1,097,774 |
| 2026 | National Science Foundation | Grant or other assistance | STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES) 47.076 | GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) -THE NATIONAL SCIENCE FOUNDATION (NSF) GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) IS A HIGHLY COMPETITIVE, FEDERAL | $1,072,944 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | RESOURCE FOR STRUCTURE-BASED COMPUTATIONAL DRUG DISCOVERY AND DESIGN (RSD3) - PROJECT SUMMARY AUTOMATED DOCKING IS A COMPUTATIONAL METHOD THAT IS NOW ROUTINELY | $1,040,213 |
| 2026 | National Aeronautics and Space Administration | Grant or other assistance | SCIENCE 43.001 | EXECUTE A BALANCED SCIENCE PROGRAM BASED ON DISCIPLINE-SPECIFIC GUIDANCE FROM THE NATIONAL ACADEMIES OF SCIENCES ENGINEERING AND MEDICINE ADMINISTRATION PRIO | $990,000 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | CTSA K12 PROGRAM AT THE SCRIPPS RESEARCH INSTITUTE - PROJECT SUMMARY/ABSTRACT SCRIPPS RESEARCH TRANSLATIONAL INSTITUTE’S (SRTI’S) K12 PROGRAM AIMS TO DELIVER AN | $971,929 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | COMBINING MEMBRANE ENV VACCINE REGIMENS TO ELICIT MULTIPLE BNAB LINEAGES AND CONSISTENT CROSS-NEUTRALIZATION OF HIV - PROJECT SUMMARY DEVELOPING A PREVENTATIVE | $940,820 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | OPTIMIZING VACCINE-ELICITED CROSS-NEUTRALIZING ANTIBODY RESPONSES TO THE HIV ENV TRIMER APEX - SUMMARY FOR AN EFFECTIVE HIV VACCINE, BROADLY NEUTRALIZING ANTIBO | $937,343 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | LINKS BETWEEN RRNA AND TRNA MODIFICATIONS, CODON USE, TRANSLATION, AND METABOLISM IN CANCER CELLS - PROJECT SUMMARY POST-TRANSCRIPTIONAL RNA MODIFICATIONS ARE A | $931,737 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GLYCOENGINEERING CORE A(1,3)-FUCOSE MOTIFS TO ENHANCE HIV-1 ENVELOPE VACCINE IMMUNOGENICITY - PROJECT SUMMARY THE HIV-1 ENVELOPE GLYCOPROTEIN (ENV) IS THE SOLE | $931,385 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | AN INNOVATIVE APPROACH TO IDENTIFY CORRECTORS OF METABOLIC COMPLICATIONS IN HIV - SUMMARY SINCE THE INTRODUCTION OF COMBINATION ANTIRETROVIRAL THERAPY (ART) TH | $930,383 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ANTIBODY-GUIDED DESIGN OF A HUMAN ASTROVIRUS VACCINE - PROJECT SUMMARY VIRAL DIARRHEAL DISEASES CAUSE SUBSTANTIAL GLOBAL MORBIDITY AND MORTALITY. DIARRHEAL DISE | $919,605 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | INVESTIGATION OF THE RULES DICTATING PLASMA CELL LONGEVITY - PROJECT SUMMARY GUT-ASSOCIATED LYMPHOID STRUCTURES, SUCH AS PEYER'S PATCHES, ARE SOME OF THE MAJOR | $919,363 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CHEMOPROTEOMIC DISCOVERY AND FUNCTIONAL ANALYSIS MICROBIOTA BILE ACID-PROTEIN TARGETS IN HOST IMMUNITY - PROJECT SUMMARY KEY METABOLITES FROM INTESTINAL MICROBI | $919,254 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | RESTORING NEURONAL DEGRADATIVE CAPACITY AS A THERAPEUTIC STRATEGY TO TREAT PRION DISEASE - PRIONOPATHIES ARE RARE HUMAN NEURODEGENERATIVE DISEASES (ND) CHARACTE | $919,051 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | CHEMICAL PROTEOMIC PLATFORMS FOR RADICALLY EXPANDING CANCER DRUGGABILITY | $916,320 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ABERRANT PROTEIN S-NITROSYLATION MEDIATES GENE-ENVIRONMENT INTERACTIONS IN AD/ADRD - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) AND AD-RELATED DEMENTIAS (ADRD) RE | $913,756 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISCOVERING SMALL MOLECULES ACTIVATORS OF STRESS RESPONSIVE SIGNALING | $905,683 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | NOVEL B CELL EPITOPE DISCOVERY AGAINST HUMAN CORONAVIRUSES - PROJECT SUMMARY HUMAN CORONAVIRUSES HAVE CAUSED DEVASTATING GLOBAL PANDEMICS AND EPIDEMICS AND CON | $899,935 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A SINGLE LONG-ACTING INJECTION FOR HBV TREATMENT USING NOVEL ENTECAVIR PRODRUGS FOR PWLH - ABSTRACT THE LONG-TERM OBJECTIVE OF THIS RESEARCH IS TO DEVELOP A LON | $899,741 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GENETIC, STRUCTURAL AND FUNCTIONAL PROFILING OF THE HUMAN ANTIBODY RESPONSE TO ARENAVIRUS INFECTION - PROJECT SUMMARY ARENAVIRUSES ARE A FAMILY OF ZOONOTIC RNA | $898,803 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STRUCTURAL AND FUNCTIONAL INSIGHTS INTO MPOX ENTRY AND NEUTRALIZATION - ABSTRACT ORTHOPOXVIRUSES HAVE CAUSED DEVASTATING PANDEMICS AND OUTBREAKS THROUGHOUT HUM | $897,277 |
| 2026 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | SCALABLE FUNCTIONAL ANALYSIS OF NEUROPSYCHIATRIC RISK GENES WITH SPATIALLY INTEGRATED IN VIVO PERTURB-SEQ - ALTHOUGH NUMEROUS GENES AND LOCI ASSOCIATED WITH AUT | $890,929 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE GENERATION AND PROTECTIVE FUNCTION OF LUNG TISSUE RESIDENT MEMORY T CELLS FOLLOWING SARS-COV-2 INFECTION OR VACCINATION - PROJECT SUMMARY/ABSTRACT CORONAVIR | $890,260 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIGH-THROUGHPUT ASSAYS AND SMALL-MOLECULE DISCOVERY OF ANTIVIRAL CANDIDATES TARGETING INFLUENZA HEMAGGLUTININ - PROJECT SUMMARY / ABSTRACT INFLUENZA A VIRUSES | $886,550 |
| 2026 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | STRUCTURAL REMODELING OF NEURAL CIRCUITS VIA MULTISYNAPTIC BOUTONS - THE OVERARCHING GOAL OF THIS COLLABORATIVE PROGRAM IS TO UNDERSTAND HOW CIRCUITS IN THE MAM | $878,601 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ENANTIOSELECTIVE AND SITE-SELECTIVE C-H ACTIVATION REACTIONS WITH BIFUNCTIONAL LIGANDS - PROJECT SUMMARY HIGHLY SELECTIVE AND DIVERSE C(SP3)–H AND C(SP2)–H FUN | $874,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LEVERAGING MEMBRANE ENV LIPOSOME VACCINE DESIGN TO ELICIT MULTI-TARGET CROSS-NEUTRALIZATION OF HIV - PROJECT SUMMARY DEVELOPING A VACCINE THAT ELICITS HIV BROAD | $868,899 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CONTRIBUTIONS OF CELL TYPE AND EXOSOME SIGNALING TO PRODROMAL SYNAPTIC AND CIRCUIT CHANGES IN ALZHEIMER'S DISEASE MODELS - ALZHEIMER’S DISEASE (AD) IS CHARACTER | $865,877 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DISSECTING MECHANISMS OF ACTION OF NEXT-GENERATION SAPONIN COMBINATION ADJUVANTS. - PROJECT SUMMARY / ABSTRACT SAPONINS, TRITERPENE GLYCOSIDES ORIGINALLY ISOLAT | $865,432 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | THE PROTEIN C PATHWAY: MECHANISMS, STRUCTURE-FUNCTION, AND TRANSLATION - THE LONG-TERM OBJECTIVES OF THIS PROGRAM ARE TO CONTRIBUTE TO THERAPEUTIC PROGRESS FOR | $863,954 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DISSECTING POLYCLONAL SERA TO REVEAL CORRELATES OF PRODUCTIVE IMMUNE RESPONSES TO HIV | $863,280 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DEFINE THE INTERFACE BETWEEN PERIPHERAL NERVE TERMINALS AND METABOLIC TISSUES - PROJECT SUMMARY BRAIN-BODY CROSSTALK HAS BECOME A FRONTIER FOR BATTLING METABOLI | $860,360 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | A DRUGGABLE MITO-NUCLEAR FEEDBACK MECHANISM THAT PRESERVES MITOCHONDRIAL AND SYNAPTIC FUNCTION IN OLD-AGE - ABSTRACT MOUNTING EVIDENCE SUGGESTS MITOCHONDRIAL DE | $857,190 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | MANAGING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) THROUGH PROTEOSTASIS SIGNALING PATHWAYS - PROJECT SUMMARY/ABSTRACT: ALPHA-1-ANTITRYPSIN (AAT) DEFICIENCY (AATD) I | $855,694 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DETERMINANTS OF HIV-1 INNATE IMMUNE SENSING AND ITS ROLE IN SHAPING THE LYMPHOID ENVIRONMENT. - PROJECT SUMMARY HIV-1 HAS A LOW TRANSMISSION RATE AND MOST NEW I | $840,133 |
| 2026 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | IN VIVO PERTURB-MAP: SCALABLE GENETIC SCREENS WITH SINGLE-CELL AND SPATIAL RESOLUTION IN INTACT TISSUES - HUMAN GENETIC STUDIES HAVE PROVIDED LISTS OF GENES AND | $839,825 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DYNAMICS OF THE BACTERIAL RIBOSOME AND PROTEOME | $834,212 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MECHANISMS OF MUTANT PRION PROTEIN AGGREGATION WITHIN ENDOLYSOSOMAL PATHWAYS - ULTRASTRUCTURAL STUDIES OF HUMAN PATIENT BRAINS WITH PRION DISEASE HAVE REVEALED | $833,064 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 | INTEROCEPTIVE NETWORK THAT CO-REGULATES EMOTIONAL AND AUTONOMIC RESPONSES - OUR AUTONOMIC REGULATION OF RESPIRATION, DIGESTION, CIRCULATION, AND IMMUNE FUNCTION | $831,984 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | MAPPING BRAIN-WIDE OPIOID ACTIONS BY PROFILING NEURONAL ACTIVITIES AND IN VIVO CELLULAR TARGET ENGAGEMENT - ABSTRACT OPIOIDS ARE HIGHLY EFFECTIVE AT REDUCING PA | $830,063 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ACTIVATION OF THE PARASUBTHALAMIC NUCLEUS IN ALCOHOL DEPENDENCE | $803,309 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | INITIATION OF ANTI-ISLET AUTOIMMUNITY: REGULATION OF MHC CLASS II EXPRESSION IN THE ISLET MICROENVIRONMENT - TYPE 1 DIABETES (T1 D), A PROTOTYPIC CD4 T CELL MED | $801,662 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MICROBIOTA, PROBIOTIC AND DIETARY METABOLITE CONTROL OF ENTERIC PATHOGEN VIRULENCE - PROJECT SUMMARY KEY METABOLITES FROM MICROBIOTA, PROBIOTICS AND DIET CAN IN | $799,773 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | INVESTIGATING THE CHROMATIN REMODELING FUNCTIONS OF POLYPHOSPHATE CONDENSATES IN PSEUDOMONAS AERUGINOSA - PROJECT SUMMARY IN RESPONSE TO A VARIETY OF STRESS AND | $799,175 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | NEURPSYCHOPHARMACOLOGY-MULTIDISCIPLINARY TRAINING | $776,686 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MECHANISTIC STUDIES OF COMBINATION ADJUVANTS IN THE ESTABLISHMENT OF B CELL MEMORY - IN FULL RESPONSE TO RFA-AI-25-006, WE PROPOSE TO STUDY THE MECHANISMS OF CO | $772,010 |
| 2026 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | REDOX-MEDIATED NEUROTOXICITY OF MILITARY-RELATED TOXIC EXPOSURE IN PARKINSON'S DISEASE | $769,972 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | PHARMACOLOGIC TARGETING OF THE UPR IN OBESITY-LINKED LIVER DYSFUNCTION - SUMMARY UNHEALTHY DIETS AND INCREASINGLY SEDENTARY LIFESTYLES HAVE LED TO AN EPIDEMIC R | $766,207 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19 - WHILE THE DEVELOPMENT OF EFFECTIVE VACCINES AGAINST COV-2 IS CAUSE FOR OPTIMISM, VACCINE HESITAN | $749,787 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | TARGETED DEGRADATION OF GLYCOIMMUNE CHECKPOINTS SIGLEC-7 AND -9 FOR CANCER IMMUNOTHERAPY - PROJECT SUMMARY/ABSTRACT TARGETED DEGRADATION OF EXTRACELLULAR PROTE | $748,410 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | CHEMICAL INDUCERS OF PROXIMITY TO ANTAGONIZE FOXA1 - PROJECT SUMMARY/ABSTRACT FOXA1 IS A PROTOTYPICAL “PIONEER” TRANSCRIPTION FACTOR (TF) AND ESSENTIAL LINEAGE | $744,054 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | STABILIZED SALVINORIN ANALOGS - PROJECT SUMMARY/ ABSTRACT THIS PROPOSAL SEEKS TO EXPAND AND UNDERSTAND THE CHEMISTRY AND PHARMACOLOGY OF THE SALVINORIN CHEMOTY | $740,595 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 | DECONVOLUTION OF GALBULIMIMA BARK PHARMACOLOGY THROUGH CHEMICAL SYNTHESIS AND TARGET ASSIGNMENT - ABSTRACT THE GALBULIMIMA (GB) ALKALOIDS ARE DERIVED FROM THE | $737,132 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROBING THE PROTEINOPATHY COMPONENT OF LIGHT CHAIN AMYLOIDOSIS PHARMACOLOGICALLY - PROJECT SUMMARY IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS (AL) IS A DEGENERATIV | $732,475 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | SYNTHESIS AT THE INTERFACE OF CHEMISTRY AND BIOLOGY - PROJECT SUMMARY/ABSTRACT THIS PROPOSAL EXPLORES THREE MAJOR ASPECTS OF SYNTHETIC BIOLOGY- ALL UNDER THE RE | $732,320 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ANALYSIS OF PROTEIN INTERACTIONS IN NEURODEGENERATIVE DISEASE - SUMMARY/ABSTRACT LATE ONSET ALZHEIMER'S DISEASE (LOAD) IS THE MOST COMMON FORM OF AGE-RELATED DE | $730,133 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ROLE OF RAB27 IN GRANULOCYTE FUNCTION | $727,183 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 | DECODING VOMERONASAL ACTIVITY THROUGH AWAKE, BEHAVING AOB IMAGING. - SUMMARY: THE SENSE OF SMELL IN THE MOUSE LARGELY OCCURS THROUGH THE MAIN OLFACTORY SYSTEM ( | $723,194 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IN VIVO ENGINEERING OF B CELLS FOR THE SECRETION OF HIV BROADLY NEUTRALIZING ANTIBODIES - PROJECT SUMMARY WE HAVE DEVELOPED A NOVEL GENE THERAPEUTIC APPROACH TO | $717,704 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PHARMACOLOGIC LYSOSOMAL FLUX ACTIVATORS TO AMELIORATE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS - A COMMON MOLECULAR PHENOTYPE EXISTS FOR MOST NEURODEGENERATIVE | $713,861 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | POST-TRANSCRIPTIONAL MECHANISMS OF INTERNEURON DEVELOPMENT - ABSTRACT CORTICAL INHIBITORY INTERNEURONS (CINS) ARE CRITICAL FOR CIRCUIT FUNCTION. DESPITE TREMEN | $710,155 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | NEURAL MECHANISMS OF ENERGY EXPENDITURE-INDUCED COMPENSATORY FOOD INTAKE - PROJECT SUMMARY OBESITY IS A MAJOR PUBLIC HEALTH PROBLEM. MODULATING ENERGY EXPENDITU | $707,310 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UNUSUAL PHARMACOPHORES AND NEW TOOLS FOR CROSS-COUPLING | $704,352 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | NOVEL GENETIC PATHWAYS UNDERLYING BRAIN-GUT COMMUNICATION IN C. ELEGANS - PROJECT SUMMARY THE BRAIN HAS LONG BEEN KNOWN TO PLAY CRITICAL ROLES IN THE REGULATION | $701,896 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING GENOME STABILITY MECHANISMS AND THEIR REGULATION BY SUMO AND UBIQUITIN | $699,200 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | MOLECULAR PATHOGENESIS OF COVID-19-ASSOCIATED COAGULOPATHY AND NEW THERAPEUTIC APPROACHES - PROJECT SUMMARY MANY STUDIES HAVE HIGHLIGHTED A LARGE INCIDENCE OF H | $695,610 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STRUCTURAL AND MECHANISTIC BASIS FOR RNA SILENCING | $692,300 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ELECTROPHYSIOLOGY OF ALCOHOL IN EXTENDED AMYGDELA | $691,065 |
| 2026 | National Institutes of Health | Grant or other assistance | VISION RESEARCH 93.867 | INVESTIGATING THE ANTI-INFLAMMATORY MECHANISMS OF CALORIE RESTRICTION IN THE AGED LACRIMAL GLAND - DRY EYE IS A PREVALENT CONDITION THAT SIGNIFICANTLY IMPACTS T | $688,585 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | REVERSE ENGINEERING THE ARCHITECTURE OF INHIBITORY SYNAPSES AT NANOMETER RESOLUTION - EACH CLASS OF BRAIN CELLS COMPRISES NUMEROUS SUBTYPES WITH DISTINCT MOLECU | $687,666 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEFINING ENDOPLASMIC RETICULUM STRESS-DEVELOPMENT MITOCHONDRIA REMODELING - PROJECT SUMMARY ENDOPLASMIC RETICULUM (ER) STRESS AND MITOCHONDRIAL DYSFUNCTION ARE | $684,451 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | EDYNAMIC - SCRIPPS - EDYNAMIC (EXTRACHROMOSOMAL DNA IN CANCER) HUMAN GENES ARE ARRANGED ON 23 PAIRS OF CHROMOSOMES, BUT IN CANCER, TUMOUR-PROMOTING GENES CAN FR | $658,783 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | SINGLE NUCLEUS GENE EXPRESSION IN MODERATE AND COMPULSIVE DRUG SELF-ADMINISTRATION IN A RODENT MODEL OF HIV - SUMMARY THE ABUSE OF STIMULANTS SUCH AS METHAMPHE | $653,746 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CHEMICAL MODULATION OF PROTEOSTASIS TO PROMOTE LONGEVITY AND HEALTHY AGING - ABSTRACT NEURONAL PROTEOSTASIS IS ESSENTIAL FOR BEHAVIORAL AS WELL AS PHYSIOLOGICAL | $645,242 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CHEMOENZYMATIC GLYCAN EDITING FOR DECIPHERING BIOLOGICAL FUNCTIONS OF GLYCANS - PROJECT SUMMARY/ABSTRACT CELL-SURFACE GLYCANS PARTICIPATE IN NUMEROUS BIOLOGICA | $644,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | INTESTINE TO ADIPOSE TISSUE INTERORGAN COMMUNICATION IN HOMEOSTASIS AND OBESITY - PROJECT SUMMARY SECRETED PROTEINS COORDINATE ORGAN FUNCTIONS DURING HOMEOSTASI | $640,762 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDERSTANDING HUMAN ANTIBODY RESPONSES TO CHRONIC VIRAL HEPATITIS C - PROJECT SUMMARY HEPATITIS C VIRUS (HCV) INFECT ~1% OF THE WORLD POPULATION, PREDISPOSING T | $637,216 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ROLE OF BK CHANNELS IN ALCOHOL-INDUCED DYSMYELINATION - SUMMARY MYELINATION IS ESSENTIAL TO EFFICIENT ACTION POTENTIAL PROPAGATION AND NEURON SURVIVAL. THE BULK | $637,012 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STRUCTURE-FUNCTION STUDIES OF DELE1-MEDIATED ACTIVATION OF THE INTEGRATED STRESS RESPONSE - ABSTRACT PROTEIN HOMEOSTASIS (PROTEOSTASIS) IS TIGHTLY REGULATED BY | $632,667 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | DATA MINING AND FUNCTIONAL VALIDATION OF SCORCH DATASETS - SUMMARY THE ABUSE OF DRUGS IS ASSOCIATED WITH TREATMENT NON-COMPLIANCE, GREATER RISK OF VIRAL TRANSM | $608,652 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | ESTABLISHING A MECHANISTIC BASIS FOR ENHANCED TUMORIGENESIS UNDER CHRONIC CIRCADIAN DISRUPTION - PROJECT SUMMARY (DESCRIPTION) CIRCADIAN RHYTHMS COORDINATE BEHA | $606,729 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | FOXO TRANSCRIPTION FACTORS IN JOINT AGING AND OSTEOARTHRITIS PATHOGENESIS | $582,166 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | CANCER-SPECIFIC DEPENDENCIES WITHIN THE NURD CHROMATIN REMODELER COMPLEX: NEW TARGETS AND CHEMICAL TOOLS - PROJECT SUMMARY/ABSTRACT HISTONE DEACETYLASES (HAT) A | $580,318 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | GENE NETWORK PERTURBATIONS IN ALCOHOL DEPENDENCE - A SYSTEMS BIOLOGY APPROACH | $579,593 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MOLECULAR MECHANISMS OF TRANSTHYRETIN AMYLOIDOSIS | $566,635 |
| 2026 | National Science Foundation | Grant or other assistance | MATHEMATICAL AND PHYSICAL SCIENCES 47.049 | EXPEDIENT SYNTHESIS OF GLYCOSAMINOGLYCAN SACCHARIDES WITH DEFINED SULFATION PATTERNS FOR PROBING HUMAN PROTEIN INTERACTIONS. -RESEARCHERS FROM THE SCRIPPS RESEA | $552,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL CHARACTERIZATION OF DENDRITIC CELL HETEROGENEITY FOR T CELL-INDUCING IMMUNOTHERAPIES - PROJECT SUMMARY/ABSTRACT THE DELIBERATE HARNESSING OF HUMAN IM | $552,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDERSTANDING PLASMA CELL LONGEVITY AND THEIR ROLES BEYOND ANTIBODY PRODUCTION - PROJECT SUMMARY SECRETION OF ANTIBODIES IS A SPECIALIZED CELLULAR FUNCTION OF P | $552,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | BRIDGING THE GLYCOME AND PROTEOME WITH CHEMICAL BIOLOGY - PROJECT SUMMARY GLYCOPROTEINS AND PROTEOGLYCANS ARE IMPORTANT PROTEIN GLYCOCONJUGATES IN THE CELL. THE | $544,571 |
| 2026 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | EARLY PATHOGENIC STEPS IN XENOBIOTIC-INDUCED AUTOIMMUNITY - AUTOIMMUNITY IS THOUGHT TO RESULT FROM A COMBINATION OF GENETICS, ENVIRONMENTAL TRIGGERS, AND STOCHA | $542,761 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CONTROLLED CATALYTIC FUNCTIONALIZATION OF ALKENES AND ALKYNES - PROJECT SUMMARY/ABSTRACT FUNDAMENTALLY, A MAJOR BOTTLENECK IN THE DRUG DISCOVERY PROCESS ACROSS | $524,400 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A PROTAC STRATEGY TO COMBAT BOTULINUM NEUROTOXICITY - PROJECT SUMMARY/ABSTRACT BOTULINUM NEUROTOXIN (BONT), THE CAUSATIVE AGENT OF BOTULISM, IS THE MOST POTENT | $518,450 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RNA RECOMBINATION IN CORONAVIRUSES - RNA VIRUSES ARE EXCEPTIONALLY DIVERSE AND RAPIDLY EVOLVING. THEIR RNA-DEPENDENT RNA POLYMERASES ARE PRONE TO MUTATION, LACK | $517,611 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | SULFUR(VI) FLUORIDE EXCHANGE (SUFEX): NEW DEVELOPMENTS AND BIOLOGICAL APPLICATIONS - PROJECT SUMMARY/ABSTRACT THE CENTRAL GOAL OF THIS PROJECT IS TO DEVELOP NEW | $515,200 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ADVANCING HIV VACCINE DEVELOPMENT WITH A LIPID NANODISC PLATFORM - PROJECT SUMMARY THE ENVELOPE (ENV) GLYCOPROTEIN OF HIV IS THE ONLY VIRAL PROTEIN ON THE SURFA | $511,531 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DECIPHERING THE MOLECULAR PRINCIPLES LINKING POPZ FILAMENT STRUCTURE TO CONDENSATE FUNCTION - PROJECT SUMMARY/ABSTRACT BIOMOLECULAR CONDENSATES CRITICALLY REGUL | $506,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DECODING MEMBRANE PROTEIN FOLDING AND FUNCTIONAL PRINCIPLES USING SIMPLE DESIGNED BUILDING BLOCKS - THIS RESEARCH PROGRAM INTEGRATES PROTEIN DESIGN WITH BIOPHYS | $506,000 |
| 2026 | National Institutes of Health | Grant or other assistance | VISION RESEARCH 93.867 | MAPPING LACRIMAL GLAND IONOCYTE RNA AND PROTEIN SECRETION IN HOMEOSTASIS ANDINFLAMMATION" - PROJECT SUMMARY THE LACRIMAL GLAND (LG) IS AN EXOCRINE GLAND THAT P | $506,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ENGINEERING BROADLY CROSS-REACTIVE MONOBODIES TO REVERSE BOTULINUM INTOXICATION - PROJECT SUMMARY BOTULINUM NEUROTOXINS (BONTS) ARE POTENT BIOLOGICAL TOXINS CAP | $501,137 |
| 2026 | National Aeronautics and Space Administration | Grant or other assistance | SCIENCE 43.001 | COMPREHENDING WHY RNA BY INVESTIGATING THE PRIMITIVE CONTEMPORARIES OF RNA | $500,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | INHIBITION OR EVASION OF P-GLYCOPROTEIN-MEDIATED DRUG TRANSPORT - THE OVERARCHING GOAL OF THIS PROJECT IS TO OBTAIN A DEEP, MOLECULAR-LEVEL UNDERSTANDING OF P-G | $497,527 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MODULAR SYNTHESIS OF ANTIBIOTIC AND ANTICANCER CLASSES OF NATURAL PRODUCTS - PROJECT SUMMARY/ABSTRACT THIS PROPOSAL SUMMARIZES ONGOING PROJECTS IN OUR LABORATO | $496,800 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | "EXTENDED DOSING" IMMUNIZATION TO ENHANCE HUMORAL IMMUNITY TO NEXT-GENERATION VACCINES - PROJECT SUMMARY/ABSTRACT THE MAJORITY OF LICENSED VACCINES ARE THOUGHT | $477,610 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | NOVEL LASSA FEVER LIVE-ATTENUATED VACCINE PLATFORM WITH SAFETY FEATURES ENSURING UNBREACHABLE ATTENUATION - PROJECT SUMMARY/ABSTRACT THE MAMMARENAVIRUS LASSA (L | $469,396 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ACCELERATING DISCOVERY BY MERGING KINETICS WITH DATA SCIENCE METHODS IN CATALYTIC ORGANIC REACTIONS - PROJECT SUMMARY/ABSTRACT OVER THE PAST THREE DECADES, THE | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ROLE OF PLD3 IN NUCLEIC ACID RECOGNITION AND BRAIN FUNCTION - PROJECT SUMMARY/ABSTRACT THIS IS A R01 PROPOSAL TO STUDY THE FUNCTION OF PHOSPHOLIPASE D3 (PLD3) A | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EPIGENOMIC MODULATION OF CYSTIC FIBROSIS | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | METABOLOMICS TECHNOLOGIES TO ADVANCE BIOMEDICAL RESEARCH | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STRUCTURE-BASED IN-SILICO PREDICTION OF PEPTIDE INTERACTIONS. - INTERACTIONS BETWEEN PEPTIDES AND THEIR SUBSTRATES PLAY A CENTRAL ROLE IN MANY CELLULAR PROCESSE | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CROSSTALK BETWEEN INNATE-IMMUNITY HUMAN MICROGLIA AND ADAPTIVE-IMMUNITY TREGS IN ALZHEIMER'S DISEASE - TITLE: CROSSTALK BETWEEN INNATE-IMMUNITY HUMAN MICROGLIA | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING INFLUENZA A VIRUS BY A CARBOHYDRATE-INSPIRED STRATEGY | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | METHODS AND APPROACHES TO EXPAND THE PHARMACOLOGICAL TOOLSET - PROJECT SUMMARY OUR LABORATORY IDENTIFIES SMALL MOLECULES WITH PHYSIOLOGICAL ACTIVITY TO ADVANCE | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | STRUCTURAL CHARACTERIZATION OF LARGE EUKARYOTIC PROTEINS CONTAINING BOTH FOLDED AND DISORDERED DOMAINS - INTRINSICALLY DISORDERED PROTEINS (IDPS) ARE HIGHLY ABU | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | APPLYING SPATIAL COVARIANCE TO UNDERSTAND HUMAN VARIATION IN GENETIC DISEASE - PROJECT SUMMARY/ABSTRACT: THE FOCUS OF THIS PROPOSAL IS BASED ON OUR ONGOING EFFO | $460,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | INNATE LYMPHOCYTE RESPONSES TO EARLY-LIFE INFECTIONS - PROJECT SUMMARY STAPHYLOCOCCUS BACTERIA ARE THE PRIMARY CAUSE OF HEALTHCARE-ASSOCIATED INFECTIONS IN NEO | $460,000 |
| 2026 | National Science Foundation | Grant or other assistance | BIOLOGICAL SCIENCES 47.074 | REU SITE: SCRIPPS STRUCTURE AND FUNCTION SUMMER INSTITUTE (SFSI) -THIS REU SITE AWARD TO THE SCRIPPS RESEARCH INSTITUTE, LOCATED IN LA JOLLA, CA, WILL SUPPORT T | $458,766 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ALCOHOL-INDUCED NEUROINFLAMMATION AND AUD THERAPEUTIC MECHANISMS - ABSTRACT ALCOHOL USE DISORDER (AUD) IS A HETEROGENEOUS CONDITION RESULTING FROM THE INTERPLA | $414,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | MODULATING SIGNALING ENDOCANNABINOIDS AND FATTY ACID AMIDES | $414,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | SYNAPTIC MECHANISMS UNDERLYING SEX-DIFFERENCES IN ALCOHOL USE DISORDER - ALCOHOL USE DISORDER (AUD) IS A MAJOR PUBLIC HEALTH PROBLEM. THE CENTRAL NUCLEUS OF THE | $414,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | SCRIPPS RESEARCH TRANSLATIONAL CHEMICAL BIOLOGY - PROJECT SUMMARY/ABSTRACT SCRIPPS RESEARCH IS A LEADER IN THE FIELD OF CHEMICAL BIOLOGY. THIS LEADERSHIP IS EST | $410,671 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | EEG AND ERP MEASURES OF ALCOHOL'S EFFECTS | $385,275 |
| 2026 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | MECHANO SIGNALS REGULATING TENDON AND LIGAMENT HOMEOSTASIS - ABSTRACT MECHANO-STIMULATION IN THE MUSCULOSKELETAL SYSTEM PLAYS A MAJOR ROLE IN THE HOMEOSTASIS OF | $384,560 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | DEVELOPING ORAL DRUGS TARGETING THE INSULIN RECEPTOR USING 'BEYOND RULE OF 5' DEL LIBRARIES - INSULIN IS A LIFE-SAVING THERAPY FOR THE MORE THAN 8 MILLION AMERI | $368,500 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | ADDICTION TRAINING IN DISCOVERY, COMPUTATION, AND TRANSLATION TO MEDICINE - SUMMARY/ABSTRACT DURING THE PAST FIVE YEARS, MAJOR BREAKTHROUGHS HAVE OCCURRED IN DI | $292,462 |
| 2026 | Departmental Offices | Grant or other assistance | RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 | PROGRAMMABLE CONDENSATE REACTORS FOR RAPID TOXIN NEUTRALIZATION | $288,050 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EVALUATION OF HIV-1 ENV-C3D CONSTRUCTS ON NANOPARTICLES FOR STRUCTURE, FUNCTION AND IMMUNOGENICITY. - SUMMARY A BROADLY EFFECTIVE HIV-1 VACCINE REMAINS A HIGH P | $276,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GENERATION OF A BIOLOGICALLY CONTAINED MOUSE MODEL OF EBOLA VIRUS INFECTION FOR MECHANISTIC STUDIES - PROJECT SUMMARY DUE TO ITS HIGH MORTALITY RATE AND PERSIST | $276,000 |
| 2026 | National Institutes of Health | Grant or other assistance | MEDICAL LIBRARY ASSISTANCE 93.879 | EXPANDING BIOTHINGS AS A COMMUNITY API GATEWAY FOR SHARING BIOMEDICAL KNOWLEDGE - IN BIOMEDICAL RESEARCH, EFFECTIVE ANALYSIS OF NEW EXPERIMENTAL DATA DEPENDS ON | $276,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 | EXPLORING ENTANGLED PHOTONS FOR BIOMEDICAL QUANTUM SENSING - QUANTUM SENSING TECHNOLOGIES THAT LEVERAGE SPECIAL PHYSICS OF QUANTUM MECHANICS SHOW GREAT PROMISE | $276,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GERMLINE TARGETING FOR NEURAMINIDASE BROADLY NEUTRALIZING ANTIBODIES - THE DEVELOPMENT OF A BROAD-SPECTRUM INFLUENZA VACCINE REMAINS A SIGNIFICANT CHALLENGE. ON | $276,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOST-SPECIFIC PROFILES OF DEFECTIVE VIRAL GENOMES OF INFLUENZA VIRUS - PROJECT SUMMARY RNA VIRUSES ARE EXCEPTIONALLY DIVERSE AND RAPIDLY EVOLVING. THEIR RNA-DEP | $270,443 |
| 2026 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | CTSA POSTDOCTORAL T32 AT THE SCRIPPS RESEARCH INSTITUTE - PROJECT SUMMARY SCRIPPS RESEARCH IS BECOMING A LEADER IN THE FIELD OF TRANSLATIONAL RESEARCH. THIS LEA | $258,882 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ESTABLISH HIV INFECTION, TREATMENT, AND ENGINEERED B CELL MEMORY RESPONSES IN THE THX MOUSE MODEL - PROJECT SUMMARY A FUNCTIONAL CURE FOR HIV THAT MAINTAINS LIF | $253,256 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | THE NOCICEPTIN ORL1 SYSTEM: TREATMENT TARGET FOR RELAPSE | $251,712 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | 3D PROTEOMICS AT SINGLE CELL RESOLUTION WITH COVALENT PROTEIN PAINTING (CPP) - PROJECT SUMMARY/ABSTRACT SOMATIC MUTATIONS ALTER THE FOLDING AND THEREWITH FUNCTI | $240,043 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A MODULAR CROSS-LINKER PLATFORM FOR PROTEOME-SCALE MAPPING OF DYNAMIC PROTEIN-PROTEIN INTERACTIONS IN CELLS - PROJECT SUMMARY PROTEIN–PROTEIN INTERACTIONS (PPIS | $230,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 | DEVELOPMENT OF POTENT AND SAFE CRISPR TOOLS FOR IN VIVO GENE EDITING USING DIRECTED EVOLUTION - DEVELOPMENT OF POTENT AND SAFE CRISPR TOOLS FOR IN VIVO GENE EDI | $230,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | CONTROL OF OPIOID-MOTIVATED APPROACH AND AVOIDANCE BEHAVIOR BY NEURONAL ENSEMBLES IN THE BASOLATERAL AMYGDALA AND THEIR PROJECTION TARGETS IN THE NUCLEUS ACCUMB | $194,064 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PROXIMAL REGULATION OF INNATE IMMUNE SIGNALS IN ISCHEMIA REPERFUSION INJURY - PROJECT SUMMARY: THIS PROPOSAL EVALUATES HOW THE OBLIGATE TLR CORECEPTOR CLUSTER O | $184,000 |
| 2026 | Department of the Army | Grant or other assistance | BASIC SCIENTIFIC RESEARCH 12.431 | NEW GRANT | $170,209 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DECONSTRUCTING BRAINSTEM CIRCUITS FOR VISCERAL SENSES - PROJECT SUMMARY/ABSTRACT THE ABILITY TO TIGHTLY CONTROL METABOLIC HOMEOSTASIS IS CRITICAL FOR ANIMAL SUR | $153,360 |
| 2026 | National Institutes of Health | Grant or other assistance | 21ST CENTURY CURES ACT - PRECISION MEDICINE INITIATIVE 93.368 | THE PARTICIPANT CENTER: EMPOWERING ALL OF US RESEARCH PROGRAM PARTICIPATION ACROSS THE UNITED STATES - A. ABSTRACT THE PARTICIPANT CENTER (TPC) WILL 1) MAINTAIN | $150,000 |
| 2026 | National Aeronautics and Space Administration | Grant or other assistance | SCIENCE 43.001 | EXECUTE A BALANCED SCIENCE PROGRAM BASED ON DISCIPLINE-SPECIFIC GUIDANCE FROM THE NATIONAL ACADEMIES OF SCIENCES ENGINEERING AND MEDICINE ADMINISTRATION PRIO | $150,000 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CONTRIBUTION OF PTP1B AND HYPOCRETIN SIGNALING TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY AND SLEEP DISTURBANCES - PROJECT SUMMARY MY LONG-TERM CAREER GOAL IS TO DE | $126,900 |
| 2026 | Department of the Army | Grant or other assistance | BASIC SCIENTIFIC RESEARCH 12.431 | 85318-BB-PCS-GRANT-TITLE-GENETICALLY ENCODED, NEW-TO-NATURE LIGANDS WITH DESIGNER BIOACTIVITIES | $100,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ROLE OF PARASUBTHALAMIC ASTROCYTIC DYSFUNCTION IN ALCOHOL USE DISORDER - PROJECT SUMMARY THE INCIDENCE OF STIMULANT USE DISORDER (SUD) IN THE UNITED STATES IS O | $97,826 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DEFINING THE IMPACT OF HEPATIC ER STRESS ON THE INTEGRITY OF THE SECRETED PROTEOME - ABSTRACT. HEPATIC ENDOPLASMIC RETICULUM (ER) STRESS IS IMPLICATED IN THE ON | $76,300 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | A RADICAL PATHWAY TOWARD C-F BOND FUNCTIONALIZATION: DIRECT FLUORINE-ATOM TRANSFER - PROJECT SUMMARY/ABSTRACT THE INCORPORATION OF CARBON–FLUORINE (C–F) BONDS | $75,880 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | HOW DOES MECHANOSENSATION CONTRIBUTE TO CHOROID PLEXUS FUNCTION IN HEALTH AND DISEASE? - PROJECT SUMMARY THE CHOROID PLEXUS IS A STRUCTURE THAT EXTENDS FROM TH | $64,285 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MANIPULATING MICRORNA-TARGET INTERACTIONS TO RESCUE PROTEIN LEVELS IN HAPLOINSUFFICIENT DISORDERS - PROJECT SUMMARY/ABSTRACT: CORRECTING GENE DOSAGE IS CRUCIAL | $46,558 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | PQBP1 AS A CENTRAL REGULATOR OF INFLAMMATION IN NEURODEGENERATIVE DISEASES - PROJECT SUMMARY: NEURODEGENERATIVE DISEASES POSE SIGNIFICANT CHALLENGES TO PUBLIC H | $37,114 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IDENTIFICATION AND CHARACTERIZATION OF HOST FACTORS INVOLVED IN MAMMARENAVIRUS REPLICATION, TRANSCRIPTION, AND TRANSLATION TOWARDS THE TREATMENT OF VIRAL HEMORR | $37,114 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MAPPING MICRORNA-TARGET INTERACTIONS IN THE ZONATED LIVER - ABSTRACT THE LENS OF METABOLIC ZONATION IS EXTREMELY PERTINENT TO LIVER PATHOPHYSIOLOGY, AND CAN BE | $37,114 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | LEVERAGING IN VIVO PROTEIN TRACKING TO IDENTIFY NOVEL IMMUNE MARKERS ASSOCIATED WITH OBESITY DRIVEN DISEASE - PROJECT SUMMARY. TO DATE, BIOCHEMICAL TOOLS TO STU | $34,114 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF SOLUBLE AND MEMBRANE BOUND IMMUNOGENS TO SHEPHERD HIV-1 MPER SPECIFIC BCR MATURATION - PROJECT SUMMARY/ABSTRACT. A SMALL FRACTION OF INDIVIDUALS | $34,114 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SMAC MIMETICS AS BROAD-SPECTRUM ANTIVIRALS - ABSTRACT ANTIVIRALS THAT ARE CURRENTLY IN CLINICAL USE TARGET A LIMITED NUMBER OF VIRUSES OR VIRAL SUBGROUPS, HAVE | $13,225 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | NEUTROPHIL 2026: THE EIGHTH NEUTROPHIL INTERNATIONAL SYMPOSIUM - PROJECT SUMMARY NEUTROPHILS 2026: AN OVERVIEW OF THE 8TH INTERNATIONAL SYMPOSIUM THE 8TH NEUTRO | $8,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | INFLUENZA VIRUS RECEPTORS ON HUMAN AIRWAY EPITHELIAL CELLS | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | KLF4 IN JOINT DEGRADATION AND REGENERATION | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MECHANISTIC INVESTIGATION OF THE ROLE OF FBXW7 IN INFLAMMASOME ACTIVATION - THE NLRP3 INFLAMMASOME IS A KEY REGULATOR OF INFLAMMATORY RESPONSES. THESE INCLUDE R | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | OMICS ANALYSES OF HIV AND SUBSTANCE USE DISORDER | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ROLE OF GLUCOCORTICOID RECEPTOR-MEDIATED MRNA DECAY IN ALCOHOL DEPENDENCE - SUMMARY PHARMACOLOGICAL INHIBITION OF GLUCOCORTICOID RECEPTOR (GR) SIGNALING CAN EFF | -$5 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | AMPLIFICATIONS AND SIGNALING OF ONCOPROTEINS IN CANCER - CANCER CELLS OFTEN AMPLIFY SIGNALING PROTEINS, ALTERING CELL SIGNALING NETWORKS AND LEADING TO PROTUMO | -$1,620 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MOLECULAR MECHANISM OF PIN1-MEDIATED REGULATION OF THE NUCLEAR RECEPTOR PPARY - PROJECT SUMMARY/ABSTRACT PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR | -$18,238 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING STRUCTURAL AND MOLECULAR MECHANISMS OF THE HUMAN MULTIFUNCTIONAL MITOCHONDRIAL PROTEASE, LONP1 - PROJECT SUMMARY INTEGRATED QUALITY CONTROL (QC) SYSTEM | -$22,212 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | DISCOVERY OF METABOLIC PATHWAYS USING PHENOTYPIC SCREENING AND CHEMICAL PROTEOMICS - PROJECT SUMMARY OBESITY IS A MAJOR PUBLIC HEALTH PROBLEM THAT IS CHARACTERI | -$29,081 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEVELOPMENT OF CARBOXYL- AND AMIDE-DIRECTED C-H ACTIVATION/C-C COUPLING REACTIONS | -$37,487 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | ELUCIDATION OF THE MECHANISM OF MICROHOMOLOGY-MEDIATED END JOINING BY DNA POLYMERASE THETA - PROJECT SUMMARY DOUBLE-STRANDED DNA BREAKS (DSBS) ARE A SEVERE FORM | -$40,752 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | INVESTIGATING DNA DOUBLE-STRAND BREAK REPAIR MECHANISMS IN MAMMALIAN CELLS - PRINCIPAL INVESTIGATOR: WU, XIAOHUA PROJECT SUMMARY GROSS CHROMOSOMAL REARRANGEMEN | -$40,874 |
| 2026 | National Institutes of Health | Grant or other assistance | ALCOHOL RESEARCH PROGRAMS 93.273 | ALCOHOLISM AND STRESS: A FRAMEWORK FOR FUTURE TREATMENT STRATEGIES | -$43,920 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ALLEVIATING MITOCHONDRIAL DYSFUNCTION IN PERK-DEFICIENT NEURODEGENERATIVE DISEASE - PROJECT SUMMARY MITOCHONDRIAL DYSFUNCTION AND ENDOPLASMIC RETICULUM (ER) STR | -$62,275 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | WEST AFRICAN EMERGING INFECTIOUS DISEASE RESEARCH CENTER (WA-EIDRC) | -$1,008,157 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT | $20,850,211 |
| 2025 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | SCRIPPS CLINICAL AND TRANSLATIONAL SCIENCE HUB - PROJECT SUMMARY / ABSTRACT THE SCRIPPS RESEARCH TRANSLATIONAL INSTITUTE (SRTI) IS THE FOUNDATION FOR THE SCRIPP | $6,078,076 |
State business registration
- THE SCRIPPS RESEARCH INSTITUTE CA, Employee benefit plan sponsor (Form 5500), Filed for plan year 2025
- THE SCRIPPS RESEARCH INSTITUTE, INC. FL, Foreign nonprofit corporation (FORNP), Inactive, formed 2004-01-12
The same business name in the same state, from the state’s official registry data.
Patents
569 US patents filed in the last 20 years; 9 security interests recorded against them.
- The Scripps Research Institute 569 patents, 2008-05-27 to 2026-10-20 FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12767704 | Antibodies capable of binding HIV GP120 and methods of use thereof | 2026-10-20 | PTBLXML, file of 2026-10-20 |
| US 12760046 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | 2026-10-13 | PTBLXML, file of 2026-10-13 |
| US 12758557 | Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 2026-10-13 | PTBLXML, file of 2026-10-13 |
| US 12752014 | Disruption of CD28-sialoside ligand complexes to enhance T cell activation | 2026-10-06 | PTBLXML, file of 2026-10-06 |
| US 12748111 | Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors | 2026-09-29 | PTBLXML, file of 2026-09-29 |
| US 12741937 | Tautomeric ligand enables biomimetic C—H hydroxylation with molecular oxygen | 2026-09-22 | PTBLXML, file of 2026-09-22 |
| US 12728169 | Immune cell receptor antibodies conjugated to high affinity siglec-ligands | 2026-09-08 | PTBLXML, file of 2026-09-08 |
| US 12723039 | Small molecule inhibitors of SLC15A4 with anti-inflammatory activity | 2026-09-01 | PTBLXML, file of 2026-09-01 |
| US 12715907 | Rapid elicitation of broadly neutralizing bovine antibodies to HIV Env | 2026-08-25 | PTBLXML, file of 2026-08-25 |
| US 12679869 | Recombinant HIV Env polypeptides and their uses | 2026-07-14 | PTBLXML, file of 2026-07-14 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
22 US trademarks, 11 live.
- The Scripps Research Institute 22 marks, CA FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| S | 98373960 | 2024-01-24 | Registered | TRTYRAP, file of 2026-04-03 |
| S CALIBR-SKAGGS | 98373944 | 2024-01-24 | Registered | TRTYRAP, file of 2026-04-03 |
| CALIBR-SKAGGS | 98373920 | 2024-01-24 | Registered | TRTYRAP, file of 2026-04-03 |
| SCIENCE CHANGES EVERYTHING | 88780257 | 2020-01-31 | Registered | TRTDXFAP, file of 2026-10-03 |
| POWERMOM | 88165380 | 2018-10-23 | Abandoned | TRCFECO2, file of 2024-03-27 |
| POWERMOM | 88165372 | 2018-10-23 | Abandoned | TRCFECO2, file of 2024-03-27 |
| SCRIPPS RESEARCH | 88123931 | 2018-09-19 | Registered | TRTYRAP, file of 2026-04-03 |
| SCIENCE CHANGING LIFE | 88030317 | 2018-07-09 | Registered | TRTYRAP, file of 2026-04-03 |
| SKAGGS GRADUATE SCHOOL | 88030306 | 2018-07-09 | Registered | TRTDXFAP, file of 2026-06-12 |
| CALIBR | 88030292 | 2018-07-09 | Registration cancelled | TRTDXFAP, file of 2026-10-14 |
The newest marks of the trademark owners above, matched to this record by name (and state).
Drug and device company payments (Open Payments) Fuzzy
- Teaching hospital receiving payments: THE SCRIPPS RESEARCH INSTITUTE, $2,143,807 in 26 records, 2019–2024 (same name and state)
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | THE SCRIPPS RESEARCH INSTITUTE | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Payment recipient | THE SCRIPPS RESEARCH INSTITUTE | CA | Open Payments (drug and device company payments) | name and state |
Matched by name (and state) or EIN only; a shared name is not proof of the same person or organization.
Comments